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RIASSUNTO  
 
Nel corso degli ultimi anni, numerosi geni regolatori dello sviluppo embrionale e 
della differenziazione cellulare si sono rivelati importanti mediatori della 
tumorigenesi. Lo studio di questi geni ha inoltre evidenziato l’esistenza di 
meccanismi comuni nella regolazione di diversi sistemi differenziativi, tuttavia 
ancora poco si conosce della loro funzione ed interazione. Una migliore 
comprensione dei meccanismi d’azione e delle relazioni fra geni regolatori è quindi 
fondamentale per chiarire anche la loro possibile implicazione in processi 
patologici. Il mio progetto di tesi di Dottorato si è inserito nel contesto di ricerca del 
laboratorio diretto dalla Dr.ssa Maria Cristina Magli che si interessa da diversi anni 
della funzione di alcuni di questi geni nell’ematopoiesi ed in altri sistemi cellulari, 
in particolare a livello di cellule staminali e progenitori. Durante la mia tesi ho 
sviluppato una serie di studi sul ruolo di Kit, un protoncogene che codifica il 
recettore tirosin-chinasico per il fattore di crescita Stem Cell Factor (SCF). Il 
pathway regolativo SCF/Kit riveste un ruolo chiave nella regolazione di diversi tipi 
di cellule staminali come le ematopoietiche, germinali e cardiache. Inoltre Kit è 
espresso anche nell’intestino, a livello delle cellule interstiziali di Cajal, e 
recentemente è stato evidenziato per Kit un’attività oncogenica nello sviluppo dei 
tumori stromali gastro-intestinali (Gastrointestinal stromal tumors; GISTs).  
Al fine di studiare la regolazione e la funzione di Kit ho utilizzato una linea 
transgenica murina, generata nel laboratorio diretto dal Prof. Sergio Ottolenghi, 
nella quale il gene repoter “enhanced green fluorescent protein (GFP)” è espresso 
sotto il controllo di regioni di regolazione di Kit. 
Il primo obiettivo della mia tesi è stato verificare se il transgene Kit/GFP sia 
espresso nelle cellule staminali ematopoietiche (HSC) del midollo osseo (BM) e del 
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fegato fetale. Tramite analisi citofluorimetriche, saggi clonogenici e saggi di 
ripopolazione in vivo, ho dimostrato che il transgene è efficientemente espresso 
nelle HSC sia durante lo sviluppo embrionale che nella vita adulta. Inoltre, i 
risultati da me ottenuti forniscono la prima evidenza funzionale di una espressione 
differenziale di Kit nelle HSC rispetto ai progenitori ematopoietici, riproducendo 
quindi i pattern di espressione di altri importanti marcatori di cellule staminali. 
Questi risultati, in aggiunta ai dati precedentemente ottenuti riguardo alla 
espressione del transgene in altri tipi di cellule staminali e progenitori, dimostrano 
che il transgene contiene le regioni regolatorie necessarie per una corretta 
espressione che ricapitola l’espressione del gene Kit endogeno. Per queste ragioni, 
il nostro modello transgenico può essere considerato un prezioso sistema in vivo per 
“monitorare” cellule staminali e progenitori durante lo sviluppo e la rigenerazione 
tissutale. 
In quest’ottica, il modello Kit/GFP è stato da me impiegato per analizzare il 
trafficking fra midollo osseo e cuore in seguito ad infarto miocardico (MI). Infatti, 
il secondo obiettivo della mia tesi e’ stato determinare se cellule del BM possano 
contribuire a ripopolare il pool di cellule staminali cardiache Kit+ in seguito a MI. 
A tal fine abbiamo trapiantato midollo Kit/GFP in animali riceventi wild type che, a 
distanza di quattro mesi, sono stati sottoposti a infarto miocardico. Dopo 2-3 
settimane gli espianti cardiaci sono stati cresciuti in vitro; nelle colture cellulari 
derivate dai cuori infartuati abbiamo evidenziato la presenza di cellule GFP+ capaci 
di proliferare estesamente e di generare "cardiosfere", ovvero strutture contenenti 
cellule staminali cardiache, progenitori e cellule differenziate. Tutte le cardiosfere 
derivate da cuori infartuati sono risultate fluorescenti, cioè derivate dal midollo 
osseo trapiantato. Le stesse cardiosfere si sono inoltre dimostrate capaci di 
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differenziare in cellule cardiache in vitro e in vivo, se iniettate in topi riceventi 
secondari wild type sottoposti a MI. Questi risultati indicano che, almeno in seguito 
a un danno a livello cardiaco, cellule derivate dal midollo osseo possono migrare 
nel tessuto cardiaco danneggiato e generare cellule con proprietà analoghe a quelle 
delle cellule staminali cardiache "endogene". 
In conclusione, il nostro modello transgenico Kit/GFP costutuisce un potente 
strumento per lo studio delle dinamiche differenziative delle cellule staminali dei 
tessuti normali e patologici in cui il pathway Kit/SCF riveste una fondamentale 
funzione regolativa. 
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ABSTRACT 
 
A significative number of genes that regulate embryo development and cell 
differentiation are also involved in oncogenesis. A considerable amount of data 
about these genes also strongly supports the idea that common regulatory 
mechanisms are involved in the control of different cell systems, although very 
little is known about their function and interaction. Elucidating the mechanisms of 
action and relationships among these regulatory genes is therefore a critical issue in 
order to understand their role in oncogenesis. My PhD thesis has been developed in 
Dr Magli’s laboratory within a project aimed at investigating the role of common 
regulatory mechanisms involved in hematopoiesis and other cell systems, 
particularly at the level of stem and progenitor cells. During my thesis I carried out 
studies focused on the Kit gene, encoding a tyrosine-kinase receptor for the Stem 
Cell Factor (SCF). The SCF/Kit signaling pathway is essential in the regulation of 
multiple stem cell types, such as hematopoietic, germinal, cardiac etc. Kit is also 
expressed in the gut, at the level of interstitial cells of Cajal, and it has been 
indicated as an oncogene in the development of gastrointestinal stromal tumors 
(GIST). 
In order to study Kit regulation and function I used a transgenic mouse line, 
generated in the laboratory of Prof Sergio Ottolenghi, expressing the reporter gene 
“enhanced green fluorescent protein” (GFP) under the control of Kit regulatory 
elements. The first question addressed in my thesis is whether the Kit/GFP 
transgene is expressed in hematopoietic stem cells (HSCs) of bone marrow (BM) 
and Fetal Liver (FL). Using FACS analysis, in vitro clonogenic assays and in vivo 
bone marrow repopulation assays, I showed that indeed the transgene is 
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functionally efficient in HSCs both during embryonic development and in adult 
life. Furthermore, the results provide the first evidence suggesting that Kit might be 
differentially expressed in HSCs and in progenitor cells, thus reproducing the 
expression patterns of other important stem cell markers. Moreover, these findings, 
together with our previous data on the expression of the transgene in other types of 
stem and progenitor cells, demonstrate that the transgene contains the regulatory 
regions required for a correct expression that recapitulates the expression of the 
endogenous Kit. Thus, our transgenic model provides a powerful in vivo system to 
track stem and progenitor cells during development and tissue regeneration. 
In this view, the second issue addressed in my thesis concerns the trafficking 
between bone marrow and heart after myocardial infarction (MI). In order to 
determine whether BM cells could contribute to repopulate the Kit+ cardiac stem 
cell pool after myocardial infarction we transplanted BM cells from transgenic 
Kit/GFP mice into wild type recipients that, following hematological reconstitution, 
were subjected to MI. After 2-3 weeks, heart explants were grown in vitro and 
cultures of the infarcted hearts contained GFP+ cells that were able to undergo 
extensive proliferation and generate typical "cardiospheres", that is structures 
including stem cells, progenitors and some differentiated cells. Indeed, all the 
cardiospheres developed from the damaged hearts were fluorescent, demonstrating 
their origin from the transplanted BM. Furthermore, they contained cells capable of 
differentiating into cardiac cells both in vitro and in vivo, upon injection into 
secondary wild type recipients subjected to myocardial infarction. 
These results indicate that, at least following heart damage, bone marrow cells can 
home into the heart and generate cells with properties of resident cardiac stem cells. 
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In summary, our transgenic model provides a powerful in vivo system to monitor 
the expression of a gene critical for signaling in several stem/progenitor cells. 
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1. INTRODUCTION 
1.1 Stem Cells 
 
In the last few years, great emphasis has been placed on the isolation, 
characterization and potential therapeutic uses of stem cells. 
Stem cells are defined as cells capable of both self-renewal and commitment to 
differentiation into one or more mature cell types. However different types of stem 
cells can be distinguished on the basis of their developmental potential. 
The real totipotent stem cells are the fertilized oocyte (the zygote) and its 
descendants of the first two divisions. These cells are indeed able to form the 
embryo and the trophoblasts of the placenta. After about 4 days, these totipotent 
cells begin to specialize, forming a hollow ball of cells, the blastocyst, and a cluster 
of cells called the inner cell mass (ICM) from which the embryo develops. The 
ICM cells are considered to be pluripotent, namely able to differentiate into almost 
all cells that arise from the three germ layers, but they are unable to give rise to the 
placenta and supporting tissues. ICM cells can be maintained in culture and the cell 
lines derived, known as embryonic stem (ES) cells, are also considered to be 
pluripotential. In the adult, most tissues have multipotential stem cells, defined as 
cells capable of producing a limited range of differentiated cell lineages appropriate 
to their location. Also adult stem cells are heterogeneous with respect to 
developmental potential. For example, small intestinal stem cells can produce all 
four indigenous lineages (Paneth, goblet, absorptive columnar, and 
enteroendocrine), while central nervous system (CNS) stem cells have tri-lineage 
potential, giving rise to neurons, oligodendrocytes, and astrocytes. At the bottom of 
the stem cell hierarchy are unipotential stem cells, capable of generating one 
specific cell type. Examples are epidermal stem cells in the basal layer that produce 
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only keratinized squames and certain adult hepatocytes that have long-term 
repopulating ability (Overturf et al., 1997). Tissue-specific stem cells appear to be 
present in most organs of the body, and share some common properties: 
(1) Stem cells are a self-maintaining population. 
This is achieved if, on average, each stem cell division gives rise to one 
replacing stem cell and one transit-amplifying cell. Equally well, stem cell 
numbers would remain constant if only symmetrical divisions occurred, 
provided that each time a stem cell gave rise to two daughter transit-amplifying 
cells, another stem cell gave rise to two daughter stem cells. 
(2) Stem cells are a small percentage of the total cellularity. 
 In the mouse small intestine, there are perhaps 4–5 stem cells in a ring near the 
bottom of the crypt (Bjerknes and Cheng, 1999) out of a total crypt population 
of about 250 cells. Likewise, in skeletal muscle, satellite cells comprise about 
5% of all nuclei. In the bone marrow, the multipotential hematopoietic stem cell 
(HSC) is even more rare, with a frequency of perhaps 1 in 104-105 bone 
marrow cells. 
(3) Stem cells are undifferentiated.  
In most tissues, stem cells do not have the specialized functions of the progeny 
that they originate.  
(4) Stem cells are slowly cycling but highly clonogenic.  
In theory, it would seem prudent to restrict stem cell division because DNA 
synthesis can be error-prone. Thus, in many tissues we see that stem cells divide 
less frequently than transit-amplifying cells. In the intestine, stem cells cycle 
less frequently than transit-amplifying cells, located more luminally (Wright, 
2000) and in human epidermis, integrin-bright cells have a lower level of 
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proliferation as compared to other basal cells. In hair follicles, the hair shaft and 
its surrounding sheaths are produced by the hair matrix, which is itself 
replenished by the bulge stem cells. The bulge cells divide less frequently, but 
are more clonogenic than the transit-amplifying cells of the hair matrix (Oshima 
et al., 2001), thus showing an extensive proliferative ability. 
In many tissues and organs, the identity of the stem cells has remained either 
elusive or at least equivocal. However, in the bone marrow the identification of 
cells with the properties of self-renewal and multi-lineage differentiation potential 
is well advanced. Indeed, such cells were functionally defined in the mouse back in 
1961 by Till and McCulloch (Till and McCulloch, 1961) as cells that, upon 
transplantation, were able to form multilineage hematopoietic colonies in the spleen 
of lethally irradiated animals [colony forming units – spleen (CFU-S)].  
In human bone marrow, the sialomucin CD34 is a hematopoietic cell surface 
antigen that has been extensively exploited for the selection of long-term 
repopulating cells with multi-lineage potential, although not all HSCs express this. 
Nowadays, murine HSCs are empirically recognized on the basis of their 
immunoprofile and known as KLS cells (selected using several markers; 
Kit+/Lin¯/Sca-1+). An alternative method for enriching HSCs exploits the fact that 
some cells have evolved a cellular protection mechanism against toxic metabolites 
and xenobiotics. This mechanism involves the activity of efflux pumps that belong 
to the ATP-binding cassette (ABC) superfamily of membrane transporters, and 
such cells are able to efflux a combination of Hoechst 33342 and Rhodamine 123, 
thus appearing at the bottom left corner of a dual parameter FACS analysis – hence 
called the side population (SP)(Bunting, 2002). SP cells have been found in many 
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other tissues, and the association between SP phenotype and stemness seems to be 
true in most of these tissues. 
In the central nervous system, neural stem cells and probably their transit-
amplifying descendants express both the intermediate filament nestin and a 39 kD 
RNA-binding protein known as Musashi1 (Kaneko et al., 2000; Keyoung et al., 
2001). Musashi was first identified in Drosophila and thought to be responsible for 
the asymmetric divisions of sensory organ precursor cells (Sakakibara et al., 1996); 
it may also be a marker for intestinal crypt stem cells. 
A tissue that has been traditionally considered completely post-mitotic is the heart. 
However, in the last few years a number of studies suggested the presence of a 
cardiac stem cell population capable of (re)generating the cardiac tissue throughout 
life, raising the possibility to speculate about new potentially therapeutic strategies 
for cardiac repair. Initial evidence, though in part controversial, has been presented 
that bone marrow cells injected into damaged myocardium or mobilized into the 
circulation may transdifferentiate into heart cell types (Orlic et al., 2001; 
Wojakowski et al., 2004; Wang et al., 2006; Kawada et al., 2004). Additional, 
exciting approaches for cardiac repair have been raised by the remarkable discovery 
that the heart contains a reservoir of stem and progenitor cells. These cells are 
positive for various stem/progenitor cell markers (Kit, Sca-1, Isl-1, and Side 
Population -SP- properties)(Hierlihy et al., 2002; Martin et al., 2004; Beltrami et 
al., 2003; Oh et al., 2003; Matsuura et al., 2004; Messina et al., 2004; Smith et 
al., 2007; Laugwitz et al., 2005), propagate in vitro and develop phenotypic 
features of heart cells after differentiation in vitro or in vivo. Cardiac stem and 
progenitor cell types characterized so far (Hierlihy et al., 2002; Martin et al., 
2004; Beltrami et al., 2003; Oh et al., 2003; Matsuura et al., 2004; Messina et 
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al., 2004; Smith et al., 2007; Laugwitz et al., 2005) exhibit significant differences 
in their immunophenotypic, developmental and biological properties. Thus, the 
heart probably contains various types of stem and progenitor cells. This is in 
agreement with the emerging consensus that more than one stem cell may be 
present in a particular tissue (Cai et al., 2004), and with recent evidence that heart 
endothelial, cardiac and muscle cells may arise from a hierarchy of 
multipotent/bipotent stem progenitor cells (Moretti et al., 2006; Kattman et al., 
2006; Wu et al., 2006). 
The developmental origin(s) of stem and progenitor cells of the adult heart has been 
studied only to a very limited extent (Parmacek and Epstein, 2005). Mouse chimera 
experiments suggest that most (at least 95%) cardiomyocytes are derived from a 
relatively small embryonic founder population, ruling out any major contribution to 
the adult cardiomyocyte population from “immigrant” non-cardiac stem cells, at 
least under physiological conditions (Eberhard and Jockusch, 2005). On the other 
hand, several findings, including the presence of cardiac chimerism in patients 
receiving allogeneic bone marrow transplantation, suggest that immigrant bone 
marrow-derived cells could behave, under pathological conditions leading to heart 
damage, as precursors of cardiac stem cells (Quaini et al., 2002). 
Recently (Mouquet et al., 2005), Mouquet et al showed that in mice transplanted 
with labelled GFP+ bone marrow GFP+ cells home to the heart after infarction, and 
replenish the depleted pool of SP, Sca1+, CD31+ or CD31¯ cells, which are known 
to include a very small population of CSC (Pfister et al., 2005). However, they did 
not demonstrate the replenishment of the functional CSC pool by the transplanted 
cells. Thus, the important issue of extra-cardiac sources of CSCs, following cardiac 
damage, still needs to be addressed. If extra-cardiac cells can be induced, not only 
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to migrate to the heart, but also to reconstitute a pool of extensively replicating 
CSCs, exciting therapeutic possibilities may arise. 
 
1.1.2 Tumor stem cells 
 
During the last years, a growing body of evidence indicate that also neoplastic 
tissues can harbour stem cells: in particular, it is now commonly accepted that such 
"tumor stem cells" are responsible for drug-resistance and recidive after treatment 
in cancer patients. However, already back in 1971, McCulloch and collaborators 
noticed that only 1 in 100 to 1 in 10,000 murine myeloma cells had the ability to 
form colonies in vitro. Moreover, it had previously been demonstrated that only 1–
4% of transplanted murine lymphoma cells formed colonies in spleens of recipient 
animals (Ianus et al., 2003; Park et al., 1971; Bruce and van der Gaag, 1963; Ianus 
et al., 2003; Park et al., 1971). This low clonogenic potential was also observed in 
human leukemias (Sabbath et al., 1985; Griffin and Lowenberg, 1986). 
Furthermore, at this time, it was also found that solid organ cancer cells vary in 
their ability to proliferate in similar assays: for example, only 0,1%-0,02% of cells 
isolated from solid tumors (such as lung, ovarian and brain tumours) were capable 
of forming colonies in standard soft-agar assays (Hamburger and Salmon, 1977). 
These observations suggested the hypothesis that the whole cell population of a 
tumor could originate from a few tumor stem cells. Based on functional and 
immunophenotypic analysis of cell subpopulations with modern technologies, 
cancer has started to be increasingly considered as a stem-cell disorder, in which 
the continuous growth and propagation of the whole tumour depends on a small 
population of self-renewing cancer stem cells.  
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The HSC was the first adult somatic stem cell to be described. The existence of 
cancer stem cells was also first described in the hematopoietic system. The 
demonstration of a leukaemia-initiating cell, now commonly referred to as the 
leukaemia stem cell (LSC), in AML and other leukemias, along with the 
subsequent identification of cancer stem cells in breast and central-nervous-system 
(CNS) tumours, provides evidence for the broad applicability of the cancer-stem-
cell model. John Dick and collaborators used the non-obese diabetic (NOD)/SCID 
mouse xenotransplantation stem-cell assay system, to demonstrate that in human 
AML there are LSC populations that can reproduce all the AML characteristics 
when transplanted in recipient mice (Hamburger and Salmon, 1977; Lapidot et al., 
1994). This methodology has been fundamental to fractionate leukemia cells and 
test them for "stemness", thus demonstrating that only CD34+CD38– cells from 
AML are true LSC. In addition, a hyerachical organization of cells in AML has 
been postulated, similar to that existing in normal hematopoiesis, and this analogy 
seems to indicate that normal HSC can be the target for transformations leading to 
AML (Bonnet and Dick, 1997). Subsequently, several other groups contributed to 
define the LSC phenotype in AML: CD34+, CD38¯, IL-R+, CD71¯, HLA-DR¯, 
CD117¯ (Jordan et al., 2000; Blair et al., 1997; Blair et al., 1998; Blair and 
Sutherland, 2000). In addition, LSC have more recently been characterized in acute 
limphoyd leukemias (ALL) (Cox et al., 2004) and chronic myeloid leukemias 
(CML) (Jamieson et al., 2004). 
 A similar model has been hypothesized also for solid tumor, using the same criteria 
adopted for the definition of LSC. However, the identification of stem cells in non-
hematopoietic tissues has been rather challenging, due to the lack of knowledge for 
specific cell markers. Nevertheless, tumor stem cells have been identified in breast, 
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brain and colon cancer (Al Hajj et al., 2003; Hemmati et al., 2003; Ignatova et al., 
2002; Singh et al., 2003; Singh et al., 2004; O'Brien et al., 2007; Ricci-Vitiani et al., 
2007). Breast cancer stem cells (BCSC) have been identified on the basis of the 
expression of membrane antigens and the ability to form tumors after injection into 
adipose mammary tissue of (NOD)/SCID mice. Less than 100 ESA+, Lin–, CD24–
/low, CD44+ cells are capable of generating tumors histologically similar to the 
original when transplanted into (NOD)/SCID mice (Al Hajj et al., 2003; Hemmati 
et al., 2003; Ignatova et al., 2002; Singh et al., 2003; Singh et al., 2004). Moreover, 
cells re-derived from these tumors are still capable to generate tumors in secondary 
and tertiary recipients. These experiments demonstrated the long term self-renewal 
activity of BSCS. 
In the nervous system, it is possible to isolate and propagate stem cells as 
"neurospheres", i.e. clonal cell aggregates derived from a single Neural Stem Cell 
(NSC) (Reynolds and Weiss, 1992). Recently, tumor NSCs have been isolated from 
pediatric tumors. They form neurospheres in culture, that have the ability to 
generate neurons and glia, and show a higher proliferative and self-replicative 
potential with respect to normal NSC. Tumor NSC have also the ability to form 
tumors in neonatal rat brain in vivo (Hemmati et al., 2003; Ignatova et al., 2002; 
Singh et al., 2003). These cells express CD133 (Singh et al., 2003), a NSC marker, 
and it has been recently demonstrated that only CD133+ subpopulations have the 
ability to regenerate tumors in (NOD)/SCID mice (Singh et al., 2004). 
CD133 seems to be an important marker also in colon cancer cells (Ricci-Vitiani et 
al., 2007; O'Brien et al., 2007). To assess the presence of cancer stem cells in colon 
cancer, the group of J. Dick used renal capsule transplantation in immunodeficient 
NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). 
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Purification experiments established that all CC-ICs were CD133+; the CD133¯ 
cells, that comprised the majority of the tumor cells, were unable to initiate tumor 
growth. In limiting dilution analysis it was shown that there is one CC-IC in 5.7 x 
10(4) unfractionated tumor cells, whereas there is one CC-IC in 262 CD133+ cells, 
representing >200-fold enrichment. CC-ICs within the CD133+ population were 
able to maintain themselves as well as differentiate and re-establish tumor 
heterogeneity upon serial transplantation (O'Brien et al., 2007).  
Thus, it is realistic that in the next future the identification of new markers and new 
in vitro and in vivo assays will lead to the identification of other tumor stem cell 
populations in solid tumors.  
 
1.1.3 Hematopoietic stem cells and hematopoiesis 
 
The best-characterized stem cells are those responsible for blood cell production. 
All experimental strategies and conceptual paradigms applicable to stem cells in 
general were first defined in the hematopoietic system. The hallmark properties of 
the HSC were defined in 1963 by Till and Mc-Culloch (Siminovitch et al., 
1963). They defined HSCs as cells that are individually capable of both self-
renewal and multilineage differentiation, yielding greatly expanded numbers of 
lymphocytes, myeloid cells, and erythrocytes. In fact, around 2 × 1011 erythrocytes 
and 1010 white blood cells must be replaced each day to maintain adult human 
hematopoiesis. Terminally differentiated cells are by themselves incapable of 
further growth and must, therefore, be replaced through proliferation and 
development of HSCs (Goldman, 1982). The process, by which stem cells give rise 
to terminally differentiated cells, occurs through a hierarchy of progenitor cells, 
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often overlapping in their hematopoietic capacity (Dexter et al., 1984; Golde, 
1991). During commitment, cells can undergo extensive proliferation and 
sequential differentiation, accompanied by a decrease in self-renewal capacity. The 
primary function of this transit population is to increase the number of mature cells 
produced by each stem cell division (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The immediate progeny of HSCs in adult bone marrow are the common myeloid 
precursor (CMP) and the common lymphoid precursor (CLP) (Akashi et al., 2000; 
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Hao et al., 2001; Manz et al., 2002). CLP is thought to give rise to all lymphoid 
lineage (B, T and NK), but little is known about its development (Spangrude and 
Cooper, 2000). CMP can be associated with 2 cells that can form in vivo (CFU-S) 
and in vitro (CFU-Mix) colonies containing multiple cell types. CFU-S (Colony 
Forming Unit-Spleen) can produce colonies on the spleen of irradiated mice 
injected with BM cells (Till and McCulloch, 1961). In particular, at 7-8 days after 
transplant most spleen colonies contain mature cells of a single lineage, 
predominantly erythroid, whereas by day 12, the majority of the colonies are 
composed of multiple cell types. Furthermore, late-appearing colonies do not 
represent further development of the early clones, since most of the day 7-8 spleen 
colonies disappear within the subsequent 72 hours. Therefore the early-appearing 
colonies derive from monopotent progenitors, whereas colonies present at day 11 or 
later originate from multipotential cells (Magli et al., 1982; Metcalf, 1999). The 
other pluripotent progenitor is the CFU-Mix (Colony Forming Unit-Mix) that 
generates mixed colonies in cultures containing an appropriate cocktail of 
cytokines. CMP gives rise to progenitors committed to the generation of 
erythrocytes and megakaryocytes (MEP) or granulocytes and macrophages (CFU-
GM). These cells, capable of developing along more than one lineage, undergo 
commitment and become progressively restricted to a specific differentiative fate, 
such as Colony Forming Unit-Granulocyte (CFU-G) and Colony Forming Unit-
Macrophage (CFU-M), the direct precursors of granulocytes and monocytes, 
respectively. Similarly, two stages of different maturation have been identified 
within the erythroid lineage: an early cell (Burst Forming Unit-Erythroid or BFU-
E) and a late precursor (Colony Forming Unit-Erythroid or CFU-E) capable of 
forming large and small erythroid colonies, respectively.  
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Less than 0.01% of the hematopoietic cells in BM are pluripotent stem cells capable 
of long-term proliferation and self-renewal. In vitro clonogenic assays are a 
powerful means to quantitatively and qualitatively study a broad spectrum of 
progenitors (Metcalf, 1999), but they do not sustain HSC growth. Long-term 
cultures (LTC) in liquid media can detect primitive cells (LTC-initiating cells, 
LTC-ICs), however these cells represent a rather functionally heterogeneous 
population and the relationship between LTC-ICs and in vivo repopulating stem 
cells is not clear (Bhatia et al., 1997). The only valid test for HSCs is an in vivo 
assay that demonstrates the capacity for complete and sustained (>4 months) 
regeneration of the lymphohematopoietic system following transplantation into 
lethally irradiated histocompatible recipient. In particular, in competitive 
repopulation strategies the cells being evaluated are co-injected with genetically or 
phenotypically distinguishable reference cells. These reference cells serve the dual 
purpose of exerting a selective pressure to identify HSCs in the test population that 
possess superior proliferation potential, and enable stem cells to be identified 
among small grafts (<103 enriched HSCs) that may not on their own be sufficiently 
radioprotective as to allow their detection at later times (Harrison et al., 1978; 
Harrison et al., 1993). This approach demonstrated that a single donor stem cell can 
repopulate all the hematopoietic lineages for the entire lifespan of primary and 
secondary recipient animals. This method, named competitive repopulation assay, 
has given an estimated stem cell frequency of approximately 1 in 104 - 105 murine 
BM cells (Harrison et al., 1988; Harrison and Zhong, 1992; Okada et al., 1993; Kim 
et al., 2000). 
There are a number of studies supporting the concept of cell cycle dormancy of 
stem cell: this allows the use in vivo or in culture of cytotoxic drugs such as 5-
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fluorouracil (5-FU) and hydoxyurea, that selectively kill dividing cells to eliminate 
many of the more mature cells that are typically rapidly dividing. Administration of 
5-FU to mice typically results in a 5- to 10-fold increase in the frequency of HSCs 
in the BM cells obtained 2–4 days later and this strategy is commonly used to 
obtain enriched mouse HSC populations prior to other selection methods (Lemieux 
and Eaves, 1996). 
Despite many exhaustive studies, researchers have yet to find a single molecular 
marker that is expressed exclusively by HSCs. However, there are several markers 
whose expression is gained (or lost) at different rates as primitive hematopoietic 
cells differentiate. By targeting various combinations of markers, it has thus 
become possible to subdivide this functionally heterogeneous mixture of cells into 
more homogeneous subpopulations. Primitive hematopoietic cells, including HSCs, 
do not express a variety of surface markers that are associated with the terminal 
maturation of specific blood cell types. Lack of expression of a number of these 
lineage (Lin) markers, which in combination include all of the mature 
hematopoietic cell types (RBCs, T-cells, B-cells, natural killer cells, monocytes, 
and granulocytes), can thus be used to distinguish immature cells from the more 
abundant differentiated cells in most populations of hematopoietic cells. Selection 
of Lin¯ cells typically gives a 20- to 500- fold enrichment of HSCs depending on 
the combination of Lin markers used (Morrison et al., 1995). The sialomucin CD34 
was the first marker to be recognized on primitive hematopoietic cells: it is 
expressed in a subpopulation of cells containing both stem cells and early 
committed progenitors. Transplant studies in several species, including baboons 
and mice, have shown that long-term marrow repopulation can be provided by 
CD34 selected cells (Berenson et al., 1988). CD34 selection has been adopted as a 
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means to enrich for stem cells in clinical transplantation protocols. However, 
several recent studies suggest that there may be human and murine stem cells that 
do not express CD34. Xenograft repopulation assays using fetal sheep and immune-
deficient mice have been crucial for the identification of human CD34¯ stem cells 
capable of long-term repopulation and multilineage differentiation in vivo. 
Moreover, these cells were also able to repopulate secondary recipients, attesting to 
the extensive self-renewal potential of the engrafting cells (Nakauchi, 1998; Sato et 
al., 1999; Tajima et al., 2001). These results both in mouse and human suggest that 
CD34 may be a marker of activated and/or cycling stem cells, and that CD34+ stem 
cells can revert to quiescent CD34¯ state (Sato et al., 1999). The same controversy 
holds true for another stem cell marker, CD38, whose expression might be 
influenced by stem cells activation state (Tajima et al., 2001). It is well established 
that the majority of murine BM HSCs express Stem Cell Antigen-1 (Sca-1), Kit 
(Stem Cell Factor Receptor) and Thy-1. Thus, isolation of adult BM cells on the 
basis of a single marker, for instance Sca-1 or Kit, can provide a significant one-
step enrichment of HSCs, but to discriminate between HSCs and various subsets of 
lineage-committed progenitors and mature blood cells, strategies that exploit the 
use of specific combinations of markers are required. In the mouse, the Lin¯ Sca-1+ 
Thy-1low Kit+ population of bone marrow cells includes essentially all cells with the 
ability to repopulate irradiated mice (Uchida and Weissman, 1992). It has also been 
shown that single Lin¯ Kit+ Sca-1+ mouse BM cells can reconstitute stable and long 
term, multi-lineage hematopoiesis after transplantation in 10–20% of transplanted 
mice (Szilvassy et al., 2003). This repopulation frequency of <100% suggests that 
either the Lin¯ Sca-1+ Thy-1low Kit+ cells are not all HSCs, or that some of the cells 
have transiently lost their engrafting potential, or that only a random portion of 
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transplanted cells will successfully home to appropriate niches in the BM and 
proliferate to form detectable clones of differentiated progeny. Even pure HSC 
populations are likely to show dynamic changes in cell-surface antigen expression 
as well as functional heterogeneity. As discussed previously, the regulated 
expression of the mouse CD34 antigen independent of HSC function is one notable 
example. Therefore, caution must be taken when attempting to extrapolate the 
phenotypic profiles of HSCs. Apart from cell-surface antigen expression, primitive 
hematopoietic cells from mouse, humans, and other species have been identified 
and isolated based on their ability to efflux certain fluorescent dyes, such as 
Rhodamine-123 (Rho) and Hoechst 33342 (Ho). The majority of the HSCs in adult 
human and murine tissues are Rho¯/lo (Spangrude and Scollay, 1990). Adult BM of 
many species also contain a rare population of Ho¯/lo cells that have been 
designated as SP (Goodell et al., 1996). SP cells in the BM of adult mice are 
primarily CD34¯ and are highly enriched in their HSC content (Goodell et al., 
1996). 
The same procedure has been adopted to successfully isolate SP populations from 
non-hematopoietic tissues as muscle, brain, liver, lung and gut (Gussoni et al., 
1999; Asakura et al., 2002), thus suggesting that SP phenotype is not characteristic 
of hematopoietic cells (Jackson et al., 2001). 
Recently it has been shown that, among SP cells, the so-called "Tip-SP" population 
can be regarded as a more purified HSC population. Single CD34¯ Lin¯ Sca-1+ Kit+ 
cells have been proven to long term repopulate an irradiated recipient in 96% of the 
cases (Matsuzaki et al., 2004). However, a recent report showed that CD34¯ LSK 
cells are distributed almost equally between SP and non-SP population fractions, 
showing the same repopulative potential. Despite no information was provided 
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respect CD34+ LSK cells activity in SP and non-SP cells, the main indication seems 
to be that SP is a powerful tool for quick isolation and concentration of HSC, but 
SP should not be considered exclusively as a characteristic phenotype for HSC 
(Morita et al., 2006). 
A new combination of Signaling Lymphocyte Activation Molecule (SLAM) family 
antigens has been recently utilized by Morrison and collaborators to separate 
hematopoietic mature, progenitor and stem cell populations within bone marrow 
and fetal liver cells (Kiel et al., 2005; Kim et al., 2006). Particularly, the 
CD150+CD244¯CD48¯ fraction seems to harbour almost all the hematopoietic 
stem cells, while multipotent and committed progenitors are, respectively, 
CD150¯CD244+CD48¯ and CD150¯CD244+CD48+. This simple antigen 
combination also allowed the direct characterization of the hematopoietic niches in 
bone marrow and spleen sections (Kiel et al., 2005). Furthermore, the study of 
SLAM receptors expression in non-hematopoietic tissues seems to indicate that 
CD150, CD244, and CD48 are not pan-stem cell markers, as they were not 
detectably expressed by stem cells in the fetal or adult nervous system (Kim et al., 
2006). 
 
1.1.4 Ontogenesis of HSC 
 
The mammalian embryo contains at least two spatially separated sources of 
hematopoietic cells (Dzierzak, 2002). As it has been known for many years, 
subsequent to gastrulation and mesoderm formation, the first hematopoietic cells 
are generated in the yolk sac around embryonic day E7.5 (Palis and Yoder, 2001). 
These primitive erythrocytes produced in the yolk sac from putative hemangioblasts 
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(the common mesodermal precursor of endothelial and hematopoietic lineages) 
provide a temporary embryonic hematopoietic system. The first autonomous 
generation of more complex (lymphoid-myeloid-erythroid) hematopoietic 
progenitors and adult repopulating hematopoietic stem cells (HSCs) occurs later in 
the embryo proper in the para-aortic splanchnopleura (PAS) and aorta-gonad-
mesonephros (AGM) region. The first HSCs capable of long term repopulation in 
adult irradiated recipients are found in the AGM at E10.5, and expand over the time 
until fetal liver is colonized by a wave of HSCs between day E11.5 and day E13. 
HSCs hugely expand in the fetal liver until birth, when hematopoiesis is almost 
exclusively sustained by the BM (Dzierzak et al., 1998; Ema and Nakauchi, 2000). 
Thus, the independent and multiple emergent hematopoietic events in the extra-and 
intraembryonic tissues suggest that these sites play different roles in the 
development of the rapidly expanding hematopoietic system in the mammalian 
embryo. Understanding the direct precursors of HSCs may provide insights into 
expansion strategies for these clinically relevant cells. Several recent studies have 
provided a detailed phenotypic description of HSCs in the mouse AGM, YS, and 
FL. Indeed, all HSCs in the AGM are Sca-1/GFP+ (de Bruijn et al., 2002), Kit+ 
CD34+ (Sanchez et al., 1996), Runx1+ (North et al., 2002), SCL+ (Sanchez et al., 
2001), and Gata-2+ (Ling et al., 2004; Minegishi et al., 1999). Most or all HSCs are 
CD45+, CD31+, and VE-cadherin+ (North et al., 2002). The characterization of 
functional HSCs and the localization of these cells within the embryonic tissues 
indicate the possible phenotype of the direct precursors of HSC. The vascular 
endothelial co-localization of Sca-1/GFP (de Bruijn et al., 2002) along with Runx1, 
CD34, CD31, VE-cadherin (North et al., 2002) suggests that the direct precursors 
of HSCs are endothelial cells or ‘hemogenic endothelium’. The vascular 
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endothelium of the human embryo also has blood-forming potential (Oberlin et al., 
2002). However, these cells may not be fully functional endothelial cells and may 
just take on endothelial characteristics temporarily as they transit through the vessel 
wall. North et al. (North et al., 2002) showed that mesenchymal cells lying just 
beneath the ventral aortic endothelium could be the direct precursors of HSCs. 
These cells are Runx1+ (lacZ knock-in marker) and functional HSCs could be 
sorted based on a mesenchymal phenotype (CD45¯, CD31¯, and VE-cadherin¯). A 
more recent study suggests that HSCs are generated in Gata-3 and AA4.1 
expressing hematopoietic foci underlying the ventral aorta (Bertrand et al., 2005). 
While transplantation data show that these cells from the subaortic patches have 
some adult repopulating activity in adult recipients (0.4–1.9% engraftment), they 
are clearly not as potent as the Runx1+ or Sca-1/GFP+ AGM HSCs that provide up 
to 100% engraftment of irradiated adult recipients. Thus, the precursor cells to the 
fully potent HSCs found in the aortic endothelium and hematopoietic clusters may 
be cells localized in the subaortic patches and mesenchyme underlying the aorta. 
These cells may acquire mature HSC function as they progress towards the aortic 
endothelium and emerge in the hematopoietic clusters. In the chick embryo, it was 
shown with DiI and retroviral marking approaches that cells in the hematopoietic 
clusters arise from the aortic endothelium (Jaffredo et al., 1998). While DiI tracing 
experiments in cultured whole mouse embryos have established a lineage relation 
between endothelial cells and primitive erythroid cells (Sugiyama et al., 2003), no 
DiI lineage tracing studies have established this relation for emerging 
hematopoietic clusters or functional HSCs. Another candidate precursor to AGM 
HSCs is the mesoangioblast (Minasi et al., 2002). Such cells were clonally isolated 
from the E10 mouse dorsal aorta and when introduced into chick embryos, donor 
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cells associated with the vasculature of the host, blood and hematopoietic tissues, 
along with chondrocytes, bone cells, and muscle cells were found. While the ability 
of aortic endothelial cells to give rise to hematopoietic clusters is well documented 
[reviewed in (Kubo and Alitalo, 2003; Nishikawa, 2001)], this finding, together 
with more recent temporal and spatial frequency mapping data (Mendes et al., 
2005) demonstrates that the aorta contains cells with a wider differentiation 
potential. As such, the mesoangioblast may be a precursor to the hemangioblast or 
within the AGM to ‘hemogenic endothelium’. 
 
1.1.5. Regulation of HSCs. 
 
Over the years, several models have been advanced, proposing that hematopoietic 
lineage determination is driven extrinsically (through growth factors, stroma, or 
other external influences), intrinsically or both (Ogawa, 1993; Ogawa, 1999; Tenen 
et al., 1997). Within the hematopoietic microenvironment, the "niche", early 
precursors are maintained in specific compartmentalized niches where they interact 
with other cell types and with components of the extracellular matrix (Taichman 
and Emerson, 1998; Potocnik et al., 2000). The microenvironment has been 
reported to influence survival, proliferation, and differentiation (Torok-Storb et al., 
1999). Despite some important progress, the genetic and cellular mechanisms that 
influence stem cells either to differentiate into developmentally restricted 
progenitor cells or to self-renew to replace cells that become committed to 
differentiation are still poorly understood.  
The ability of adult stem cells to both self-renew and differentiate is critical for 
tissue homeostasis. The stem cell population would become depleted if cell 
differentiation overwhelmed self-renewal. Similarly, unchecked stem cell self-
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renewal would expand the stem cell population excessively, risking tumorigenesis 
(Jones and Fuller, 2004). An important function of the stem cell niche, therefore, is 
to regulate the balance between cellular self-renewal and differentiation. One 
mechanism that ensures this balance is the control of asymmetric/symmetric stem 
cell division. Asymmetric division means that stem cells divide into 2 daughter 
cells; one daughter cell remains in the niche as a stem cell and the other leaves the 
niche to produce a large number of progeny. Symmetric division means that stem 
cells divide into 2 identical daughter cells, both remaining in the niche as stem 
cells. Switching between symmetric and asymmetric division can occur in multiple 
stem cells that occupy the same niche under different physiological conditions 
(Watt and Hogan, 2000; Fuchs et al., 2004). In Drosophila germ stem cells, the first 
stem cell population that has been demonstrated to be strictly regulated by a niche, 
cell division is asymmetric or symmetric depending on whether the orientation of 
the mitotic spindle is perpendicular or parallel to the interface between the stem cell 
and its niche. The mechanisms underlying the establishment of cell polarity and 
spindle orientation are complex and, in some cases, appear to involve overlapping 
subsets of factors including adenomatous polyposis coli (APC), centrosomin, and 
adherens junction–related cadherins and catenins (Fuchs et al., 2004; Wallenfang 
and Matunis, 2003; Yamashita et al., 2003). Whether stem cells normally undergo 
asymmetric division in mammals as they do in invertebrates is yet to be 
determined. The impact of the niche size on controlling the number of stem cells 
supports the model that stem cells, at least in the hematopoietic system, most likely 
execute asymmetric division under normal physiological conditions (Zhang et al., 
2003; Calvi et al., 2003). 
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There are 2 classifications of HSCs, namely, long-term and short-term. Long-term 
HSCs (LT-HSCs) are capable of contributing to hematopoiesis for months or even 
a lifetime. Short-term HSCs (ST-HSCs) have a reconstitution ability that is limited 
to several weeks (Morrison and Weissman, 1994; Christensen and Weissman, 
2001). LT-HSCs are maintained primarily as quiescent or slow-cycling cells, while 
ST-HSCs are actively cycling (Passegue et al., 2005). Data from conditional 
inactivation of bone morphogenic protein (BMP) receptor type IA (BMPRIA) mice 
reveal that an increase in the number of spindle-shaped N-cadherin+ CD45– 
osteoblastic (SNO) cells, a subset of osteoblastic lining cells, in the trabecular bone 
area correlates with an increase in the number of LT-HSCs, suggesting that SNO 
cells function as a key component of the niche to support HSCs (Zhang et al., 
2003). Similarly, overexpression of parathyroid hormone (PTH) and PTH-related 
protein (PTHrP) receptor leads to increased osteoblast numbers, resulting in a 
parallel increase in the number of HSCs in the PTH/PTHrP receptor (PPR) 
transgenic mouse model (Calvi et al., 2003). Both studies point to the dependence 
of LT-HSCs on the osteoblastic niche. It appears that the ability of the osteoblastic 
niche to retain stem cells in a quiescent state is an important mechanism in 
maintaining sufficient stem cells (Arai et al., 2004).  
Additional evidence supports the view that the osteoblastic niche plays a key role in 
sustaining and maintaining HSCs. Visnjic and colleagues have demonstrated that 
HSCs, and, consequently, the hematopoietic system, rely on osteoblasts for support 
(Visnjic et al., 2004). This result came from studies of transgenic mice that 
specifically express the herpesvirus thymidine kinase (TK) gene in developing 
osteoblasts under the control of the collagen αI promoter (Col2.3TK). The 
advantage of the Col2.3TK mice is the ability to inducibly ablate osteoblasts with 
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ganciclovir (GCV), which triggers TK function. Loss of osteoblasts in GCV-treated 
Col2.3TK mice led to substantial decrease in the number of lymphoid, erythroid, 
and myeloid progenitors (including osteoclast progenitors) in the BM, followed by 
a decrease in the absolute number of HSCs (although the percentage of HSCs 
appeared only slightly changed) and reduced BM cellularity. After withdrawal of 
GCV, osteoblasts reappeared in the bone, as did hematopoiesis in the BM. These 
observations further support the role of osteoblasts in the maintenance of HSCs and 
regulation of hematopoiesis, although the authors did not perform functional assays 
to test HSCs in this model. In another study osteoblasts were shown to facilitate 
engraftment of HSCs in an allogeneic environment. After purified osteoblasts were 
cotransplanted with marrow stem cells into allogeneic mouse strains, the 
transplanted recipient mice demonstrated excellent long-term survival, absence of 
disease, and complete engraftment by the donor cells. It appeared that the 
hematopoietic progenitor cells could engraft lethally irradiated mice, but these cells 
could not cross the MHC antigen barrier in the absence of cotransplanted 
osteoblasts (El Badri et al., 1998). 
Hematopoiesis and vascularization occur concurrently during development. In fact, 
HSCs and endothelial cells are derived from the same progenitor cells 
(hemangioblasts) at the embryonic stage and are closely related to the ontogeny of 
hematopoiesis that occurs in the yolk sac, aorta-gonad-mesonephros, placenta, fetal 
liver, spleen, and adult BM (Hristov and Weber, 2004; Lacaud et al., 2001; Li, 
2005). Indeed, HSCs expressing SLAM markers were detected on the osteoblastic 
surface of trabecular bone as well as adjacent to sinusoidal endothelial cells (Kiel et 
al., 2005). This is consistent with another study in which explanted endothelial cells 
were able to maintain HSCs in culture (Li et al., 2004). Together these observations 
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support the model that HSCs may use either osteoblasts or endothelial cells as their 
niche under different circumstances (Wagers, 2005). The discovery that sinusoid 
endothelial cells have the potential to act as part of an alternative HSC niche 
together with the known osteoblastic niche support a previously proposed model in 
which the osteoblastic niche provides a quiescent microenvironment and the 
vascular niche promotes proliferation and further differentiation (Kopp et al., 
2005). This model is exemplified in studies of thrombopoietin mutant (TPO–/–) 
mice, which revealed that reconstitution of thrombopoiesis under stress involves 
recruitment of HSCs to the sinusoid endothelial surface. This action involves 
MMP-9, which mediates release of Stem Cell Factor (SCF), the soluble ligand for 
Kit. In this study HSCs left the osteoblastic niche and translocated to the vascular 
niche, where they differentiated into megakaryocyte progenitors for further 
megakaryocyte maturation as well as platelet release (Avecilla et al., 2004; Kopp et 
al., 2005). Other studies also support a more prominent role for osteoblasts in 
maintaining HSC quiescence and suggest that the sinusoidal endothelium promotes 
proliferation and differentiation of stem and progenitor cells by providing a more 
nutrient-rich microenvironment, with higher concentrations of oxygen and growth 
factors and in which mature blood cells are ultimately released into the peripheral 
circulation (Kopp et al., 2005; Abkowitz et al., 2003). A second plausible function 
for the vascular niche is to assist HSCs in transendothelial migration, important 
during both homing and mobilization (Lapidot et al., 2005; Cancelas and Williams, 
2006). A third function of the vascular niche is assigned to cells located outside of 
the BM medullary space, such as in the spleen. These cells might serve to replace 
the BM niche when the BM niche is under stress, such as with marrow suppression 
(Kiel et al., 2005). Splenomegaly concomitant with extramedullary hematopoiesis 
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is a common phenomenon in both humans and genetically mutant mice that suffer 
from BM hematopoietic failure. Based on these observations it is reasonable to 
hypothesize that endothelial cells may also function as a “backup” niche to support 
HSC expansion and produce a large number of progeny for hematopoiesis when the 
BM is under stress. 
It is well known that HSC circulation involves HSCs leaving the BM, entering the 
vascular system (mobilization), and returning to the BM (homing). However, the 
underlying physiological function of these events is not well understood (Wright et 
al., 2001). The BM vascular structure provides a barrier between the hematopoietic 
compartment and the peripheral circulation. Most primitive HSCs remain 
physiologically quiescent within the BM niche; however, a portion of HSCs leave 
this resting pool and initiate the process of mobilization (Heissig et al., 2002; Arai 
et al., 2004; Wagers, 2005). There are some controversial reports suggesting that 
mobilized HSCs may be more quiescent than those that remain in the BM. 
Evidence to support this notion comes mainly from a study in which the CD34+ 
marker was used to identify HSCs and progenitors (Steidl et al., 2002). Since the 
population of CD34+ cells included numerous progenitor cells, the comparison of 
the cell cycle profile of the CD34+ cells residing in BM and in circulating 
peripheral blood in this study might not reflect the most primitive HSCs. Indeed, 
Weissman and colleagues have definitively shown in mice that mobilized HSCs are 
more proliferative than LT-HSCs in BM by comparing highly purified BM LT-
HSCs and mobilized HSCs (Passegue et al., 2005).  
Multiple signaling and adhesion molecules are involved in stem cell–niche 
interactions. Well-studied signaling molecules involved in niche regulation include 
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SCF/Kit, Jagged/Notch, Ang1/Tie2, extracellular Ca2+ and Ca2+ receptors (CaR), 
BMP and Wnt signalling pathway. 
SCF signaling through its receptor, Kit, has been well characterized in promoting 
both proliferation and survival of HSCs. Loss of SCF from supporting cells in steel 
mice, or loss of the receptor in HSCs in W/W mice, leads to hematopoietic failure, 
indicating essential roles for these molecules in niche function (Bernstein et al., 
1991). These results are supported by more recent work revealing a direct role for 
SCF/Kit signaling in control of HSC activation and release from the niche (Heissig 
et al., 2002). It has been shown that, following 5-FU BM suppression, SDF1-
mediated activation of Matrix metalloproteinase-9 (MMP-9) induces SCF release in 
the bone marrow, allowing recruitment of Kit+ stem/progenitors cells from the 
quiescent to proliferative niche, thus allowing differentiation and reconstitution of 
the stem/progenitor cell pool. Remarkably, in MMP-9¯/¯ mice, release of SCF and 
HSC motility are impaired, resulting in failure of hematopoietic recovery and 
increased mortality, while exogenous SCF restores hematopoiesis and survival after 
BM ablation (Heissig et al., 2002). 
Notch is expressed in primitive HSCs, while the Notch ligand Jag1 is expressed by 
mouse osteoblasts and bone marrow stromal cells. Activation of the PPR can 
increase osteoblastic cell numbers concomitant with enhanced Jag1/Notch activity, 
resulting in expansion of the HSC population (Calvi et al., 2003). This observation 
is consistent with previous reports that activation of Notch signaling is able to 
maintain undifferentiated stem and progenitor cells and expand the HSC/HPC pools 
(Li et al., 1998; Varnum-Finney et al., 2000).  
Ang-1 is expressed in osteoblasts, while Tie2, a tyrosine kinase receptor, is 
expressed in HSCs and endothelial cells. Ang-1 enhances the ability of HSCs to 
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become quiescent and can induce adhesion to osteoblastic cells through Tie2 (Arai 
et al., 2004).  
Recently, CaR was found to facilitate retention of HSCs on the endosteal bone 
surface. Deficiency of CaR in knockout mice leads to release of HSCs into the 
bloodstream. Interestingly, although CaR deficiency permitted HSC homing to BM 
in these animals, the cells were unable to remain localized to the osteoblastic niche 
(Adams et al., 2006).  
BMP and Wnt signaling pathways are also involved in stem cell regulation. BMP-4 
is expressed in osteoblastic cells, but the type of BMP receptor expressed in HSCs 
is unknown (Li and Xie, 2005). Wnt signals are important for stem cell self-renewal 
(Reya et al., 2003; Staal and Clevers, 2005), but the identity of the niche 
(osteoblastic or vascular) that expresses any of numerous canonical and non-
canonical Wnt molecules is unknown. The same is true for FGF and hedgehog, 
both of which affect HSC behavior in vitro (Bhardwaj et al., 2001; de Haan et al., 
2003). However, whether and where these factors are present as niche signals 
remain unresolved.  
The adhesion molecules important in niche function include N-cadherin/β-catenin, 
VCAM/integrin, and osteopontin/β1 integrin (OPN/β1 integrin) (Li and Xie, 2005; 
Nilsson et al., 2005; Stier et al., 2005). They may play a role either for the 
attachment of stem cells to the niche or for migration of stem cells. Two adherens 
junction molecules, N-cadherin and β-catenin, are asymmetrically localized at the 
interface between HSCs and the osteoblastic niche (Zhang et al., 2003). The 
essential roles of cadherins and β-catenin in supporting germ-line stem cells and 
determining the asymmetric division and orientation of germ-line stem cells in 
Drosophila have been reported (Yamashita et al., 2003; Song and Xie, 2002). The 
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specialized distribution of the adhesion complex composed of N-cadherin and β-
catenin suggests a potential role for these molecules in facilitating anchoring of 
HSCs to the osteoblastic niche as well as their involvement in regulating 
asymmetric division of HSCs (Muguruma et al., 2006). The precise functions of 
these adhesion molecules in this regard are yet to be determined. The role of 
integrins in mediating HSC migration and homing has been shown by blocking 
integrin function with anti-integrin antibody (Papayannopoulou, 2004). Recently, 
OPN was found to contribute to HSC trans-marrow migration toward the endosteal 
region through its interaction with β1 integrin (Nilsson et al., 2005; Stier et al., 
2005).  
The vascular niche was only recently identified (Heissig et al., 2002; Kiel et al., 
2005). As a result, the associated molecules involved in regulating HSCs within 
this niche remain largely unidentified. However, studies regarding recruitment of 
HPCs to the endothelial surface provide important insights into understanding HSC 
behavior as it relates to the vascular niche. Recruitment of HPCs to the vascular 
niche depends on FGF-4 and chemokines such as Stromal cell–Derived Factor 1 
(SDF-1; also called CXCL12) (Avecilla et al., 2004; Kopp et al., 2005).  
FGF-4 augments adhesion of megakaryocyte progenitors to the vascular niche, 
while SDF-1 is a potent chemotactic factor for the transendothelial migration of 
CD41+ megakaryocytes. FGF-4–stimulated megakaryocyte adhesion or SDF-1-
induced megakaryocyte migration can be blocked by chemical inhibitors of signal 
transduction pathways, such as PI3K, PKC, and p38 MAPK, suggesting that 
multiple downstream signaling cascades are involved. FGF-4 and SDF-1 enhance 
the expression of the adhesion molecule Very Late Antigen 4 (VLA-4) on 
megakaryocytes as well as Vascular Cell Adhesion Molecule-1 (VCAM-1) on 
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endothelial cells. VE-cadherin is essential for both proper assembly and mediation 
of adhesion of megakaryocyte progenitors to the vascular niche for survival and 
further maturation. Blocking VE-cadherin by antibodies results in impaired 
thrombopoiesis (Avecilla et al., 2004).  
HSCs also express FGFR1, -2, and -3, and FGF has been shown to be able to 
stimulate HSC self-renewal and proliferation in vitro (de Haan et al., 2003). 
Therefore it is reliable that the FGF signals emanating from the vascular niche may 
play roles in recruiting HSCs/HPCs by forming a gradient from the osteoblastic 
niche (lower FGF expression) to the vascular niche (higher FGF expression) (Kopp 
et al., 2005). This proposed regulatory role of FGF is consistent with its known 
ability to induce cell migration during embryonic development (Thisse and Thisse, 
2005).  
The ability of HSCs to mobilize and then return, or home, to the niche relies on 
specific molecular recognition, cell-cell adhesion/disengagement, transendothelial 
migration, and finally anchoring to the BM niche (Muguruma et al., 2006; Lapidot 
et al., 2005; Cancelas and Williams, 2006). The chemokine SDF-1 and its receptor 
CXCR4 (Lapidot et al., 2005; Dar et al., 2005) as well as underlying signaling 
pathways, including the Rac family molecules, regulate HSC mobilization and 
homing but also play a role in cell survival and proliferation (Lapidot et al., 2005; 
Cancelas et al., 2005). Endothelial cells, osteoblasts, and other stromal cells 
constitutively express SDF-1, while HSCs express CXCR4 (Peled et al., 1999; 
Kortesidis et al., 2005). SDF-1 generated from endothelial cells induces HSCs to 
undergo transendothelial migration mediated by E- and P-selectins (Katayama et 
al., 2003). Activation of adhesion molecules such as VLA-4 and leukocyte function 
antigen-1 (LFA-1) is also required for this process and the subsequent migration in 
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BM toward the osteoblast surface (Kopp et al., 2005). Likewise, high levels of 
SDF-1 on the surface of osteoblasts attract HSCs to return home to the osteoblast 
niche. The Rho GTPases Rac1 and Rac2, in response to SDF-1 signals, are also 
involved in regulating HSC mobilization and homing (Yang et al., 2001).  
G-CSF induces HSC and progenitor cell mobilization and is widely used clinically 
during stem cell–based transplantation procedures. Recent studies revealed that the 
mechanism involved is primarily a decrease of SDF-1 in osteoblasts, with an 
increase of SDF-1 in peripheral circulation after G-CSF treatment (Petit et al., 
2002). G-CSF also induces proteolytic enzymes such as elastase, cathepsin G, 
MMP-2, and MMP-9 (required for cells to penetrate the endothelium), which 
inactivates SDF-1 through cleavage of its NH2-terminal signal sequence 
(McQuibban et al., 2001). In addition, G-CSF could regulate SDF-1 expression in 
BM at the transcriptional level (Semerad et al., 2005; Katayama et al., 2006). 
During stem cell homing HSCs expressing CXCR4 are attracted to the osteoblastic 
niche, which expresses high levels of SDF-1 (Avecilla et al., 2004; Kopp et al., 
2005), and the adherens complex formed by N-cadherin and β-catenin may play a 
crucial role for anchoring HSCs to the osteoblastic niche (Muguruma et al., 2006; 
Zhang et al., 2003). Interestingly, a recent report showed that the sympathetic 
nervous system can actively control the attraction/release of stem cells into the 
niche, utilizing G-CSF-mediated mobilization (Katayama et al., 2006). 
How hematopoietic precursors choose their differentiation pathways is still a 
controversial issue. According to one theory, commitment is directed by an 
inductive mechanism, determinated by the microenvironment’s nature and different 
signals that lead to hematopoietic cells (Trentin, 1971; Van Zant and Goldwasser, 
1979). An alternative hypothesis considers commitment as a completely stochastic 
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event (Ogawa, 1993). Cytologic analysis of multilineage colonies of single cell 
origin showed a variety of lineage combinations, consistent with the concept that 
stem cell commitment is a stochastic process (Suda et al., 1983). Analysis of 
colonies derived from paired progenitors (two daughter cells derived from a single 
parent cell) showed dissimilar combinations of lineages in many instances (Suda et 
al., 1984). Not only were the types of lineages different but also the number of 
lineages expressed in each of the pairs of colonies differed. This observation 
indicated that the stochastic principle applies not only to the type but also to the 
number of lineages that are expressed during the differentiation process. It is 
intriguing to believe that gene expression is stochastic in early stages of 
commitment. Lineage decisions would be probabilistic depending on the random 
formation of transcription complex able to initiate transcription or to repress it. 
Some combinations of expressed or repressed genes would form an autocrine loop. 
These combinations would increase the probability of transcription of other genes 
such as growth factors receptors or integral membrane proteins, which, in turn, 
would modulate collectively the stem cell response to its niche or 
microenvironment, further reinforcing the commitment event. Then, the HSC 
genome would be in an open chromatin structure and available for binding of 
transcription factors, although at low probability (Hume, 2000; Bellantuono, 2004). 
Using the highly sensitive single cell RT-PCR approach or a quantitative real-time 
PCR method, it has been demonstrated that HSC co-expresses several lineage-
restricted gene sets (Hu et al., 1997; Cheng et al., 1996). These data indicate the 
complexity of gene expression, from which distinct patterns must emerge during 
the lineage commitment process, by selective up-regulation of the relevant gene 
cohorts, accompanied by the inactivation of others. To take into account this new 
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concept of regulation, a model for the molecular nature of the uncommitted stem 
cell “state” has been postulated (Enver and Greaves, 1998). This model proposes 
that a HSC possesses a molecular “ground state” composed of low levels of 
transcripts normally associated with the function of various mature cell lineages 
(Bonnet, 2002). According to this model, a commitment process would involve 
selection and amplification of an appropriate subset of the available transcriptional 
program, and possible repression of the remainder of the transcriptional program. 
Interestingly, the features of the ground-state model are consistent with the clinical 
description of gene expression promiscuity in certain mixed leukemias (Bonnet, 
2002). Therefore, several molecules have been shown to play roles in several 
aspects of hematopoietic development, but the elucidation of the molecular 
phenotype of the HSC has just begun. Indeed, key aspects of stem cell regulation 
are likely to be the emergent properties of interacting pathways and networks, the 
elucidation of which will require an extensive description of the genetic program 
available to the stem cell.  
 
1.2 The Kit gene 
 
The Kit proto-oncogene encodes for a transmembrane tyrosine-kinase receptor for 
Stem Cell Factor (SCF), and belongs to the same family of colony stimulating 
factor-1 receptor (CSF-1-R) and platelet derived growth factor receptor (PDGF α e 
β) (Yasuda et al., 1993). 
v-kit, an oncogene identified in the HZ4-FeSV retrovirus (Hardy-Zuckerman 4 
feline sarcoma virus), is the viral homolog of Kit (Besmer et al., 1986); this 
onocogene presents a deletion of the extracellular domain, of transmembrane 
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segment and of 50 aminoacids of the C-term. The result of this mutation is the 
continuous stimulation of proliferation, independently on SCF binding. 
In the mouse, Kit is located into the White (W) locus (Besmer et al., 1986; Chabot 
et al., 1988; Geissler et al., 1988) on chromosome 5, and the locus was 
denominated from the white spots characteristics of mice having Kit mutations that 
abolish its expression in melanocytes. 
Other mutations that produce similar alterations have been mapped on the Steel 
locus, on chromosome 10 (Zsebo et al., 1990), and subsequently it has been 
demonstrated that there is located the gene encoding for the Kit ligand, SCF 
(Flanagan and Leder, 1990; Nocka et al., 1990; Huang et al., 1990). 
SCF is encoded as a secreted signal into the extracellular matrix, or can be retained 
as transmembrane signal involved in migration and cell adhesion (Flanagan et al., 
1991): this trans-membrane SCF is composed of a signal peptide, an extracellular 
domain (189aa), a transmembrane segment (23aa) and a cytoplasmic domain (36aa) 
(Anderson et al., 1990); the soluble form of SCF is probably derived from the 
proteolytic cut of the transmembrane isoform and corresponds to its first 165 
aminoacids (Nocka et al., 1990; Williams et al., 1990). 
Upon SCF binding, two Kit protein dimerize and autophosphorylate the 
cytoplasmic domain: this recruits and phosphorylates other cytoplasmic mediators 
in a cascade leading to activation of specific transcription factors, resulting in a 
modulation of the expression of target genes (Ullrich and Schlessinger, 1990). 
 
Kit and its ligand have a primary role in the regulation of definitive hematopoiesis: 
an homozygous inactivating mutation of Kit, for example, causes perinatal death in 
mice pups due to severe anemia (Nocka et al., 1990). 
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Kit and SCF have also a role in the development of mouse embryo: disruption of 
this pathway has enormous impact in migration, proliferation and survival of 
Primordial Germ Cells (PGC) from day E9.5, melanoblasts from day E11 and 
hematopoietic precursors from day E11-E12 (Buehr et al., 1993; Mintz and 
Russell, 1957; Cable et al., 1995). 
 
1.2.2 Gene and protein structure 
 
The mouse Kit gene spans over a 80 Kb region and consists of 21 exons, with a 
coding sequence of 3 Kb (Gokkel et al., 1992). Exons have dimensions ranging 
from 100 to 200 bp, with exclusion of the 21st that is 2.3 Kb; introns are more 
variable, from 100 bp to 15 Kb. The exon-intron boundaries show the classic 
consensus sequences for splicing donors and acceptor sites (GT….AG); only one 
alternative splicing site has been identified at the exon 9 level, where a distal 
splicing donor site exist, that determines the maturation of a 12 bp longer mRNA 
(Hayashi et al., 1991). 
The nucleotide sequence of human and mouse Kit promoter does not contain 
CAAT or TATA box: in both cases a transcription-initiating site is present at -58 bp 
from the translation-initiating codon. In the mouse, a secondary transcription-
initiating site is situated at -12 bp from translation-initiating codon, while in man it 
is situated at -62 bp. 
The gene isolation allowed defining the protein structure. The Kit product is a 
145KDa transmembrane glycoprotein organised in: a signal sequence (1-22aa), that 
drives the localization of the protein in the endoplasmic reticulum; an extracellular 
domain (exon 1-9), with 9 potential N-glycosilation sites and 12 cysteines 
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randomly spaced, that give rise to 5 loop immunoglobuline-like; a transmembrane 
hydrophobic region (exon 10); an intracellular kinase domain (exon 11-20). The 
last intron codes for a C-term whose function is still controversial (Gokkel et al., 
1992). 
Regulatory sequences in cis have been identified in the promoter between +1 and -
44 positions, between -44 and -81, and between -81 and -105. In correspondence to 
these regions, consensus sequences for transcription factors (Sp-1, Ap-2) and GA-
rich elements have been evidenced (Yasuda et al., 1993). 
Similarly to the murine homolog, in the human Kit promoter regulatory sequences 
have been localized into the +1 to -200 region, containing GA-rich elements, 4 Sp-1 
binding sites and potential sites for AP-2 (Yamamoto et al., 1993). 
 
1.2.3 Kit expression and function 
 
During mouse development, Kit is expressed al low level in the pluripotent cells of 
the inner cell mass and at a higher level in PGC and hematopoietic progenitors. In 
the adult Kit is expressed in a variety of cells, such as HSC, hematopoietic 
progenitors, mastocytes, oocytes and melanoblasts (Broudy, 1997). 
Using monoclonal antibody directed against the extracellular domain of Kit, it has 
been possible to evaluate that 8% of total bone marrow cells express Kit on their 
surface. Kit is mainly expressed in undifferentiated cells, while its expression 
decreases during differentiation. Kit-/- purified HSC are not capable to give rise to 
the majority of the myeloid CFUs, while Kit is not essential for B cells 
development. In W homozygous mice hematopoiesis is not sustained after birth, 
indicating that Kit/SCF pathway is fundamental for adult hematopoiesis, 
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particularly to the maintenance of hematopoietic precursors at different stages of 
differentiation (Ogawa et al., 1991).  
Kit is expressed also in non-hematopoietic tissues, showing a comparably 
fundamental role.  
In PGC, for example, the disruption of the Kit/SCF pathway has no impact before 
day E9.5. However, after that stage of development, migration and survival of PGC 
are strongly compromised (Bernex et al., 1996). In addition, Kit has great 
importance in the regulation of normal pigmentation in the mouse as well as in 
man. Kit alterations in man produce piebaldism, an autosomal dominant disease 
that has strong homology with mouse mutation white spotting: the affected 
individuals show hypopigmentation of skin areas and white spots in the hair. This is 
due to disruption in survival and migration of melanoblasts, the melanocyte 
precursors (Fleischman et al., 1991). 
Kit seems to have a significant role also in the interstitial Cajal cells (ICC) of the 
gut, a cell population deriving from neural crests that determines the pacemaker 
activity causing phase contractions in peristalsis. It has been observed that the 
direct injection of anti-Kit antibodies can influence the contraction patterns in vitro 
of newborn mice small intestine (Huizinga et al., 1995): in addition, in W mice the 
ICCs of myenteric plexus are completely absent (Huizinga et al., 1995). These 
observation can explain the megacolon and other gut abnormalities usually 
associated to piebaldism (Bolognia and Pawelek, 1988), thus demonstrating that a 
Kit disregulation can lead to abnormalities involving different cell systems. 
Recently, Kit expression has also been evidenced in vivo in the cardiac tissue and in 
vitro in putative cardiac stem cell, both of mouse and man (Wu et al., 2006; 
Messina et al., 2004; Smith et al., 2007). Using Nkx2.5/GFP ES cells, Wu and 
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colleagues demonstrated that Nkx2.5/GFP+ ES cells at day 5 of in vitro 
differentiation can undergo smooth muscle and myocardial differentiation in vitro 
and in vivo. About 28% of these cells coexpress Kit, and it has been shown that 
Nkx2.5/GFP+ Kit+ can differentiate in vitro into cardiomyocytes. In the developing 
embryo, 13% of Nkx2.5/GFP+ from day E8.5 also coexpress Kit, while later in 
development Kit expression is dramatically decreased (Wu et al., 2006). Thus, Kit 
expression seems to be closely related to an early cardiac stem cell phenotype, at 
least during development. Experiments conducted in the adult rat heart revealed the 
presence of a population of Lin− Kit+ cells that in vitro and in vivo exhibit all the 
properties expected for cardiac stem cells. They are self-renewing, clonogenic, and 
multipotent, giving rise to a minimum of three differentiated cell types: myocytes, 
smooth muscle, and endothelial vascular cells. Moreover, when injected into an 
ischemic heart, a population of these cells or the clonal progeny of one of them can 
reconstitute a well-differentiated myocardial wall (Beltrami et al., 2003). These 
data point to Kit as a marker for cardiac stem cells, thus reinforcing the concept that 
stem cells of different tissues may have a common phenotypic “signature”. 
 
1.2.4 Oncogenic potential of Kit 
 
Since its identification Kit has been regarded as a possible oncogene (Besmer et al., 
1986), however only during the last few years Kit mutations have been related to 
the development of dysplasias and tumors.  
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal 
neoplasias of the digestive tract in man. In a multiple screening on mesenchymal 
tumors from different parts of the gastrointestinal tract Hirota and collaborators 
showed that 94% of GISTs express Kit (Nakahara et al., 1998; Hirota et al., 1998). 
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A majority of these tumors also coexpress CD34, and this observation suggested 
that GISTs could indeed originate from ICCs, that are Kit+, CD34+. In GISTs, the 
region comprised between the transmembrane domain and the tyrosine-kinase 
domain of Kit is mutated, resulting in a constitutive activation of the receptor. The 
same region showed to be mutated also in familial GISTs (Nishida et al., 1998; 
Beghini et al., 2001).  
Very recently a murine model of GIST has been generated using an activating Kit 
mutation (K641E) associated with human familial GIST. Homozygous and 
heterozygous Kit K641E mice developed gastrointestinal pathology with complete 
penetrance, and all homozygotes died by 30 weeks of age, due to gastrointestinal 
obstruction by hyperplastic interstitial cells of Cajal or GISTs. Heterozygous mice 
had less extensive ICC hyperplasia and smaller GISTs, suggesting a dose-response 
relationship between oncogenically activated Kit and ICC proliferation. 
Homozygous Kit K641E mice also exhibited loss-of-function Kit phenotypes, 
including white coat color, decreased numbers of dermal mast cells, and sterility, 
indicating that, despite oncogenic activity, the mutant form cannot accomplish 
many functions of the wild type gene (Rubin et al., 2005).  
Kit mutations seem to cause disruption of mastocyte activity, as in sporadic 
mastocytosis. Several studies conducted on groups of familial or sporadic 
mastocytosis patients indicated that only in sporadic cases a mutation in Kit codon 
816 is present, that leads to constitutive activation of the receptor (Longley, Jr. et 
al., 1999). It was also previously observed that in the mast cell leukemia cell line 
HMC-1 there are two point mutations that activate the cytoplasmic domain of Kit 
(Furitsu et al., 1993). 
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 2. AIM OF THE STUDY 
 
There is considerable interest in understanding the regulatory transcriptional and 
signalling networks which underlie stem cells properties, such as pluri-
multipotency and self renewal, as well as specificity of commitment. Elucidating 
these mechanisms is relevant both to identify oncogenes and to gain insights in the 
populations of stem cells responsible for tumour development and maintenance. 
Recently, transcriptional networks of multipotent ES cells have started to be 
analysed by chromatin immunoprecipitation assays (Bernstein et al., 2006; Lee et 
al., 2006; Boyer et al., 2006). However, this approach cannot easily be extended to 
the study of the rare and not always prospectively identifiable tissue stem cells. For 
the latter stem cells, hierarchical networks of transcription factors and signalling 
molecules have been defined by gene ablation experiments, but to date the number 
of stem cell genes whose regulation has been approached at the transcriptional level 
remains relatively small.  
Kit encodes the membrane receptor of Stem Cell Factor (SCF), a diffusible ligand. 
Kit is expressed in several stem cell types, such as Primordial Germ Cells (PGC), 
Neural Stem Cells of the Eye, Hematopoietic Stem Cells (HSC), Cardiac Stem 
Cells (CSC), etc., and several types of early committed progenitors (Broudy, 1997; 
Ikuta and Weissman, 1992; Bernex et al., 1996; Das et al., 2004; Beltrami et al., 
2003; Messina et al., 2004). In these cells, Kit function is important or even 
essential, as demonstrated by genetic mutants and functional studies (Broudy, 
1997; Wylie, 1999; Dolci et al., 1991; Ikuta and Weissman, 1992). The 
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expression of Kit in multiple stem cell types suggests that common transcriptional 
programs might regulate this gene in different stem cells. 
In a previous collaborative work, the groups of Prof Sergio Ottolenghi of Università 
Milano-Bicocca and Dr. Maria Crisitina Magli of ITB-CNR identified DNaseI 
hypersensitive sites in a region of 29 Kb of the Kit gene, including a 14 Kb of 5' 
promoter region, exon1 (124 bp) and intron 1 (14,8 Kb) (Figure2) (Cairns et al., 
2003). Those 6 sites are situated in the promoter (HS1), close to exon 1 (HS2), and 
in intron 1 (HS3-6). To better comprehend the functions of these regions of the Kit 
gene, three different constructs have been realized, utilizing enhanced Green 
Fluorescent Protein (GFP) as reporter gene. The three vectors have different 
combinations of HS sites (Figure 2): A has only HS1, B has HS1+HS2, C has 
HS1+HS2+HS3-6 (Cairns et al., 2003). 
The in vivo analysis of the transgenic embryos from the three (A, B, C) generated 
lines showed that GFP is always expressed in PGC, independently on the vector 
type, while in hematopoietic sites it is only achieved when at least HS1 and HS2 
are present. The addition of HS3-6 results in a most powerful expression. Thus, the 
addition of HS2 to the promoter is indispensable for Kit expression in immature 
hematopoietic progenitors; HS3-6 are not crucial for the expression itself, but their 
addition helps a correct identification of GFP expression in hematopoietic cells 
(Cairns et al., 2003) 
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Figure 2 Expression vectors utilized to generate Kit/GFP transgenic lines 
Construct A contains the Kit promoter and hypersesitive site HS1; B contains also 
site HS2; C contains all hypersensitive sites (Hs1-6). 
 
In the present study I wanted to characterize the Kit/GFP transgenic line C, 
containing all the HSs, as a model to study the stem cell populations in which Kit is 
expressed. The first question has been to determine whether the transgene is 
functionally efficient in hematopoietic stem cells of bone marrow and fetal liver. 
For this purpose, using FACS analysis I correlated the GFP expression patterns to 
the expression of known stem cell and progenitor markers both in fetal liver and 
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adult bone marrow. On this basis selected cell sub-populations were sorted and 
assayed in vivo and in vitro to compare their hematopoietic stem and progenitor cell 
activities.  
This study, together with other findings of our groups provide evidence that the 
Kit/GFP transgene is expressed in Primordial Germ Cells and in hematopoietic 
stem and progenitor cells (Cairns et al., 2003, Cerisoli et al., 2007a). Furthermore, 
recent observations indicate that the transgene is also active in early blastocysts 
grown in vitro, and in ES cells (unpublished observations of S.O, L.C and Dr. 
Susanna Dolci, September 2006). 
Finally, in collaboration with Dr. Elisa Messina we also showed that the same 
transgene is expressed in a population of cardiac stem (Messina et al., 2004; Cerisoli 
et al., 2007b). Indeed, taking advantage of the transgene expression both in HSC 
and in CSCs the second question addressed in this thesis regards the 
trafficking between bone marrow and heart following infarction, in order to 
determine whether bone marrow cells can home into the damaged heart and 
contribute to the regeneration of a functional cardiac stem cell compartment. 
In summary, the aim of this study has been the characterization of the Kit/GFP 
model as a powerful tool for the study of cellular regulatory dynamics in normal 
and pathological stem cell compartments. 
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3. MATERIALS AND METHODS  
3.1 Mice 
Transgenic Kit/GFP mice in which the GFP-encoding sequence was placed under 
the control of Kit regulatory elements (construct 3) have been described (Cairns et 
al., 2003). Kit/GFP mice (originally in a BDF1 background) and wild type (BDF1) 
mice were kept according to institutional regulations. Transgenic mice were 
genotyped by PCR using 5’-ACATGAAGCAGCACGACTTC-3’ and 5’-
TTGTGGCGGATCTTGAAGTT-3’ primers in the GFP sequence. For timed 
experiments on embryos, the morning when the vaginal plug was detected was 
considered to correspond to day 0.5 post coitum (E0.5) 
 
3.2 Flowcytometric analysis and cell sorting were performed with a MoFlo 
(DAKO-Cytomation) flowcytometer/cell sorter with software Summit 4.0. Total 
adult bone marrow or fetal liver cells from Kit/GFP transgenics and from non-
transgenic controls (obtained by disaggregation in PBS) were incubated with 
appropriate labelled antibodies from BD Pharmingen: PE-labelled anti-mouse LY 
6A/E (Sca-1) (D7); PE anti-mouse TER119 (LY-76); PerCP-Cy5.5 labelled anti-
mouse CD11b (Mac-1) (M1/70); APC-labelled anti-mouse CD117 (Kit) (2B8) and 
analysed by flowcytometer (Moflo). Background fluorescence levels 
(autofluorescence) were defined by comparison to appropriate non-transgenic 
control cells, stained with isotype control fluorochrome conjugated. For the 
analysis of the Side Population, bone marrow cells (3x10^ 6/ml) were incubated 
with Hoechst 33342 (Sigma), 5ug/ml for 90 min at 37°C, either in the absence 
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(experimental samples) or presence (control samples) of 50 uM Verapamil. The 
cells were then washed four times with fresh culture medium (1% FCS in 
Dulbecco's Modified Eagle's Medium), further incubated with labelled antibodies 
for 30 min at 4°C, washed again at 4°C and analysed by flowcytometer with UV 
(350 nm), 630 nm and 488 nm lasers. Data from at least 1.5x10^ 6 live cells were 
acquired. 
Cell sorting of bone marrow or disaggregated fetal liver cells from heterozygous 
transgenic embryos (identified by their bright GFP fluorescence) was performed 
after APC-labelled anti-Kit staining, and Kit+ cells were fractionated on the basis of 
levels of GFP fluorescence. 
 
3.3 In vitro colony assays 
The culture conditions have been described (Magli et al., 1982; Cairns et al., 
2003). Briefly, bone marrow cells were flushed from femurs and tibias in Iscove’s 
modified Dulbecco’s medium (IMDM) with 2% FCS and cultured at a maximum 
density of 10^4 cells/ml in IMDM containing alpha-thioglycerol, methyl cellulose, 
BSA, 5% FCS, iron-saturated transferrin, lecithin, oleic acid, cholesterol, 2 units/ml 
human recombinant erythropoietin, 10 ng/ml murine stem cell factor, and 10 ng/ml 
murine IL-3. Cultures were scored both in bright field and fluorescence at 2, 7, and 
12 days with an inverted microscope by using standard criteria. 
For in vitro colony assay of CSDCs, 100,000 fibronectin-adherent wild type cells 
were plated in 35mm dishes containing 1mL of the above described semisolid 
medium. Alternatively, single secondary CSs were dissociated and plated in 96 
multiwell plates (1 cardiosphere/well containing~0,1mL of the above described 
semisolid medium) 
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3.4 PCR analysis  
DNA was prepared from bone marrow and single or pooled CSs. Cells were 
collected into 0.5mL tubes and DNA was extracted directly by digestion in 100 µL 
of a solution containing 1X PCR buffer (Celbio), 0.01M DTT and 10mg/mL 
Proteinase K. The presence of the GFP transgene was assayed by PCR using 
(forward) 5’-ACATGAAGCAGCACGACTTC-3’ and (reverse) 5’-
TTGTGGCGGATCTTGAAGTT-3’ primers. The identity of the amplified product 
was confirmed through automatic sequencing. 
 
3.5 Bone marrow transplantation 
BDF1 female recipient mice, 8–12 weeks old, were lethally irradiated with 830 rads 
(x-ray source). Two hours after irradiation, they were i.v. injected with different 
numbers of sorted fetal liver or bone marrow cells, and 2x10^5 unsorted wild type 
BM cells as support, resuspended in Iscove’s modified Dulbecco’s medium. 
Controls were injected with cell-free suspending medium. With the exception of 
controls, and occasional transplanted mice dying in the first few days after the 
transplant, no mice died during the reconstitution period. Engrafted animals were 
killed and analyzed 4–6 months after transplantation. 
For cardiac regeneration studies, irradiated wild type recipients were tail-vein 
injected with 107 Kit/GFP bone marrow cells, resuspended in Iscove’s modified 
Dulbecco’s medium. Controls were injected with cell-free medium. Transplanted 
animals were subjected to MI 4, 5, 6 and 9 months after transplantation; after 
further 2-3 weeks, they where sacrificed and analyzed as required. To test the 
hematopoietic stem cell potential of CSs, we intravenously transplanted lethally 
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irradiated female recipients with 5x105 or 106 Kit/GFP+ suspended single cells 
derived from CSs, together with 5x104, 105 or 2x105 wild type bone marrow cells 
as support.  
 
3.6 Processing and isolation of cardiosphere forming cells 
Murine tissue was derived from infarcted or non-infarcted hearts of Kit/GFP BM 
transplanted mice and processed as previously described (Messina et al., 2004). 
Tissue was cut into 1- to 2-mm3 pieces, washed with Ca2+-Mg2+–free phosphate-
buffered solution (PBS) (Invitrogen), and enzymatically digested. Tissue fragments 
were cultured in complete explant medium (CEM) (Iscove’s Modified Dulbecco’s 
Medium [IMDM] supplemented with 20% fetal calf serum, 100 U/mL penicillin G, 
100 μg/mL streptomycin, 2 mM L-glutamine, and 0.1 mM 2-mercaptoethanol) at 
37°C in an atmosphere of 5% CO2. After a period ranging from 2 to 3 weeks a 
layer of stromal-like cells arose from adherent explants over which small, round, 
phase-bright cells migrated. Once confluent, the loosely adherent cells surrounding 
the explants were harvested by gentle enzymatic digestion with trypsin and 0.53 
mM EDTA (Invitrogen). Isolation of the CS-forming cells could be performed at 
least 4 times. These CS-forming cells were seeded at 2-3x104 cells/mL on poly-D-
lysine-coated dishes in media designed for optimal growth of CSs (Messina et al., 
2004). Upon growth on poly-D-lysine-coated dishes, many cells remained 
adherent, while others progressively gave rise, after several days, to CSs, which 
detached from the dish, floating in the culture medium. Once formed, CSs were 
individually collected, pooled and replated on fibronectin-coated flasks for fast 
expansion as adherent monolayers. Monolayers of CS-derived cells (CSDCs) were 
subsequently passaged by trypsinization and subculture at a one to two ratio. When 
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required for further analysis, secondary CSs were again obtained by subjecting 
these cells to growth on poly-D-lysine coated dishes. 
 
3.7 Lentiviral vector production 
A third-generation lentiviral vector system (kindly supplied by Professor Inder 
Verma, Salk Institute, USA) was used to label CSCs. cDNA encoding the nuclear-
localized LacZ gene was sub-cloned in place of EGFP in the vector 
pRRLsin18.cPPT.CMV.eGFP.Wpre., resulting in a plasmid designated 
pPPT.CMV.nlsLacZ. Viral vector was produced by calcium-phosphate 
coprecipitation transfection of the four lentiviral vector plasmids into 293T cells 
(ATCC). Vector-containing supernatant was collected 48 and 72 hours after 
transfection, filtered (0.45 μm, cellulose acetate, Corning) and concentrated by 
ultrafiltration (100,000 MWCO, Centricon Plus-70, Millipore). Transduction titre 
was assigned on concentrated supernatant by assessing transgene expression in 
293T cells using a limiting dilution assay in the presence of Polybrene 8ug/mL 
(Sigma-Aldrich) and found to be 5 × 108 transducing units/mL three days after 
transduction. 
 
3.8 Immunohistochemistry and microscopy 
For immunostaining, CSs and CSDCs were fixed in ethanol/methanol at 4° C for 10 
minutes and then washed twice with Ca2+ and Mg2+ free PBS. Cells were 
permeabilized by incubating with 0.1% Triton X-100 and 1% BSA in PBS three 
times for 15 min. Non-specific antibody-binding sites were blocked with 10% 
normal goat serum for 30 min following which, the primary antibodies: anti cardiac 
specific transcription factor Nkx 2.5 (Chemicon), anti cardiac Troponin (TnI, 
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Sigma), anti Smooth Muscle Actin (SMA, Chemicon) or anti-β Galactosidase (β-
Gal, Chemicon) were added and incubated overnight at 4◦ C. 
Cells were washed in solution containing 0,1% Triton X-100 and 1% BSA in PBS 
and incubated 1 hour in FITC-conjugated anti-mouse IgG or TRIC-conjugated anti-
rabbit secondary antibody (Chemicon) at room temperature. 
Confocal microscopy was performed with a Leica TCS DMIRE 2. No significant 
fluorescent signal was detectable with any of the secondary antibodies alone. 
 
3.9 Myocardial infarction, cell injection and in vivo differentiation 
GFP positive CSs (6-10/heart) were collected and expanded as adherent monolayers 
on fibronectin-coated flasks (Smith et al., 2007). Cells were transduced with virus 
PPT.CMV.nlsLacZ as adherent monolayers. Transduction efficiencies of 90% were 
achieved with a multiplicity of infection (MOI) of 20. LacZ-labelled CSDCs were 
injected into adult BDF1 mice of 10-16 weeks of age at the time of MI. MI was 
induced by ligation of the mid-left anterior descending coronary artery as 
previously described (Stull et al., 2004) Animals underwent intramyocardial 
injection under direct visualization at peri-infarct site. CSDCs (105) were injected in 
a volume of 10-15 µl of PBS, whereas control mice received 10 µL of PBS only. 
To assess engraftment and cell migration, mice were euthanized 20 days after MI. 
Mouse hearts were excised, embedded in OCT compound, frozen, and sectioned in 
8 µm slices. Tissue sections were stained with hematoxylin-eosin (H&E) and β-
galactosidase reagent. Immunostaining of tissue sections was performed with 
primary antibodies against Μyosin-heavy-chain (MHC, Sigma), and β-
galactosidase. Secondary antibodies conjugated with Alexa fluorochromes were 
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utilized (Chemicon). Confocal fluorescence imaging was performed as described 
above. 
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4. RESULTS 
 
4.1.1 The transgenic Kit/GFP gene is expressed at intermediate levels in cells 
with the immunophenotype of HSC 
 
The Kit transgene consists of 6.7 Kb of mouse promoter sequences, followed by the 
GFP gene and by additional 8 Kb sequences from the 5’ part of the first intron of 
the gene. In addition to the promoter, only approximately 4 Kb at the 5’ part of the 
intron are sufficient to drive expression of the transgene; however, mouse lines 
including all 8 Kb of the intron show more accurately regulated transcription, and 
we therefore studied one of these lines (mouse line 3 in Cairns et al., 2003) in 
detail. 
In previous work (Cairns et al., 2003), E11.5 fetal liver and adult bone marrow 
cells FACS-sorted for GFP (or GFP and Kit) expression were highly enriched for 
CFU-Mix and BFU-E. At E11.5 the number of fetal liver HSC is at most few tens 
per liver (Kumaravelu et al., 2002); we thus re-examined GFP expression at later 
stages (E12.5), when much larger numbers of HSC are present. Figure 3 shows, by 
FACS analysis, GFP versus Kit expression in fetal liver cells at approximately 
E11.75, E12.25 and E12.75.  
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Figure 3. Cytofluorimetric analysis of Kit versus GFP expression in fetal liver at different 
developmental stages 
 
At all stages, three main populations can be distinguished, based on GFP levels. 
The GFP¯ population (Figure3, green), ranges between 30% and 60% of the total, 
Kit
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depending on developmental stage, and is mostly Kit¯. On the other hand, a 
population with moderate expression of GFP (3x10^1-1x10^2 fluorescence units), 
termed GFPint, represents some 15-30% of the total at all stages, and is 
predominantly Kit¯ (blue), although some cells (black points) express moderate to 
high levels of Kit; finally, a population expressing high levels of GFP (red, GFPhigh) 
is highly represented (30% of total) at the early stage, but progressively declines 
with time, and is mostly Kit+. In conclusion, at all stages examined, Kit+ cells are 
mostly (80-90%) GFP+, though at widely variable levels of fluorescence (Figure 3). 
In contrast, Kit¯ cells are either GFP¯, or weakly GFP+.  
After E11.5, the predominant population of early Kit+ cells develops rather 
synchronously into a major population of erythroid progenitors, which start to 
express the erythroid-specific Ter119 antigen, together with Kit; at late stages, after 
E12.5, most cells still express Ter119, but have already downregulated Kit (data not 
shown). In agreement with their predominant erythroid character, Ter119+ cells 
exhibit, in Kit/GFP fetal livers, either moderate levels of GFP, or no GFP at all, at 
the developmental stages reported above (Figure 4). 
 
 
 
 
 
 
 
 
Figure 4. Ter119 versus GFP expression in fetal liver cells. 
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These data suggest that Kit expressing (Kit+/Ter119¯) progenitor cells, which 
actively transcribe the Kit/GFP gene, evolve into more mature Kit+/TER119+ cells 
that progressively downregulate the transgene, concomitantly with repression of the 
endogenous Kit gene; a proportion of Kit¯ cells, however, may retain for some cell 
divisions part of the previously accumulated GFP mRNA and protein, thus 
resulting weakly GFP+. This interpretation would be consistent with the Kit+ 
population (red) (Figure 3) evolving into the GFPint Kit-population (blue) either 
directly or through the GFPint Kit+ population (black dots). 
To better understand the characteristics of these cells, we analysed the fetal liver 
population around E12.5 with CD11b, Sca1 and Kit antibodies; in fetal liver, HSC 
are known to have a CD11b+, Kit+, Sca1+ immunophenotype (Morrison et al., 1995; 
Sanchez et al., 1996; Taoudi et al., 2005). In this analysis we adopted a very 
selective window for the definition of Kit positive versus negative cells, that 
excludes some weakly positive cells. 
Figure 5 (Fetal liver, panel v) shows that the CD11b+ population consists almost 
exclusively of intermediate, but not high level, GFP+ cells. 
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Figure 5 Cytofluorimetric analyses of Kit, CD11b, Sca1 and GFP in fetal liver. 
Panels i,ii,iii: expression of Kit versus GFP, Kit versus Sca1 and Sca1 versus GFP, respectively. 
Panel v: CD11b versus GFP. Panels iv and vi: Kit versus Sca1 expression in fractions R5 
(CD11b+/GFP+) and R10 (CD11b¯/GFPint), respectively, from panel v. The analysis of other 
fractions are shown in Figure 6 
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Figure 6. Four colors cytofluorimetric analysis of E12.5 Fetal Liver cells.  
Cells pooled from transgenic Kit/GFP livers were stained with anti-CD11b, Kit and Sca1 antibodies. 
Different cell populations, as defined by levels of GFP expression and CD11b immunoreactivity 
(Panel ii), were further analysed for Kit and Sca1 expression (panel i and panels iii-vi). Most of 
Kit+/Sca1+ cells are detected in the CD11b+/GFPint population (panel ii); in fact this population is 
7.47% of the total, and 4.78% of it is Kit+/Sca1+, showing that the latter is about 0.36% of the total 
cell population, and over 60% of the total Kit+/Sca1+ population (0.61% of the total, see Figure 5, 
panel ii). 
 
Within the CD11b¯ population, cells with the highest GFP levels (R10 in panel v) 
are highly enriched in Kit+/Sca1- cells (56% of the fraction, panel vi), whereas cells 
with intermediate GFP levels contain lower proportions of this cell type (Figure 6, 
panel v). Strikingly, within the CD11b+/GFP+ cells (Figure 5, panel v), over 50% of 
the Kit+ cells are also Sca1+ (panel iv); data in Figure 6 indicate that, overall, the 
CD11b+/GFP+ fraction includes 60% or more of the total Kit+/Sca1+ population (see 
legend to Figure 6). Thus, at E12.5 cells with an immunophenotype compatible 
with that of HSC reside in the GFPint population; the GFPhigh population is instead 
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enriched in a Kit+, Sca1¯, CD11b¯ cell type that may represent a different 
progenitor. 
We then carried out a similar analysis of adult bone marrow cell population. Here, a 
rather complex GFP expression pattern is apparent (Figure 7, right panel). 
 
 
 
 
 
 
 
Figure 7. Kit and Kit/GFP profiles in bone marrow cells from Kit/GFP mice. 
 
As in fetal liver, over 90% of Kit+ cells are also GFP+ (R3 and R2); within the Kit+ 
population, most cells are GFPhigh, whereas a minority are GFPint, and are poorly 
separated from the small Kit+/GFP¯ population. As in fetal liver, a proportion of 
Kit¯ cells are GFP+, although mostly at low-intermediate levels (4-8 x10^1 
fluorescence units) (Figure 7, right panel) and may represent cells immediately 
downstream to Kit+ progenitors, and retaining some GFP mRNA and protein.  
To better analyse the progenitor cell population, we focussed on a Side Population 
(SP) fraction, known to be highly enriched in stem and progenitor cells (Goodell et 
al., 1996; Camargo et al., 2004). Again, we used Kit, Sca1 and CD11b antibodies, 
taking into account that, in adult bone marrow, and CD11b is a lineage marker, 
absent from HSC. The tip of the SP is known to be highly enriched in stem cells 
(Camargo et al., 2004; Matsuzaki et al., 2004) in comparison to the upper part of 
SSC 
FSC 
Kit 
GFP 
 56
the SP fraction. Figure 8 shows that the cumulated fractions R1 and R3 from the SP 
(panel i) consist of over 90% CD11b¯/GFP+ cells (panel ii).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Four colors cytofluorimetric analysis of the adult bone marrow Side Population.  
Panel i: the SP can be divided in two parts for further analysis: tip (R1) and base (R3). Panel ii: 
CD11b versus GFP expression within the SP. Panels iii and iv: Kit versus Sca1 expression in 
CD11b- fractions R11 (GFPint) and R7 (GFPhigh), from the SP 
 
Within the latter population, GFPint cells (R4 in panel ii) are mostly Kit+ (panel iii), 
and over 50% of the Kit+ cells are also Sca1+. In contrast, GFPhigh cells (R7 in panel 
ii) are largely Kit+/Sca1¯ (panel iv). 
Further, analysis of the tip (R1 in panel i) of the SP shows that this fraction is 
highly enriched in Kit+/Sca1+ cells relative to the base (R3 in Figure 8, panel i) of 
the SP (compare Figure 9, panels i and ii, respectively). 
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Figure 9. Four colors cytofluorimetric analysis of the adult bone marrow Side Population.  
Panels i and ii: Kit versus Sca1 expression in cells from the tip and base of the SD, respectively. 
Panel iii: relative GFP expression in Kit+/Sca1+ (red) versus Kit+/Sca1¯ (green) cell fractions from 
the tip. Panel iv: relative GFP expression in Kit+/Sca1+ (red) versus Kit+/Sca1- (blue) cell fractions 
from the base of the SD. 
 
Importantly, the Kit+/Sca1+ population shows clearly lower levels of GFP 
fluorescence than the Kit+/Sca1¯ population (Figure 9, panels iii and iv). In 
conclusion, these results suggest that CD11b-/Kit+/Sca1+ cells (which correspond to 
the immunophenotype of HSC) express a significantly lower level of GFP than the 
Kit+/Sca1¯ population. These results suggest that HSC may be contained within the 
GFPint population. 
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4.1.2 HSC are contained in the Kit+/GFPint cell population. 
 
To evaluate the relative distribution of HSC versus progenitors in GFP+ cells of 
different fluorescence levels, we fractionated E12.5 fetal liver (Figure 10, right 
panel) and adult bone marrow (Figure 7, right panel) cells according to Kit 
expression and GFP fluorescence (high versus low) levels. 
 
 
 
 
 
 
 
Figure 10. Kit and Kit/GFP profiles in fetal liver cells from Kit/GFP mice. 
 
Cell fractions were then both analyzed in vitro by clonogenic assays and injected 
into lethally irradiated mice (together with a small number of non-transgenic total 
bone marrow cells as support) for in vivo long-term hematological reconstitution 
studies. 
After at least four months, hematological reconstitution was assessed in two ways. 
First, bone marrow from the recipient mice was plated in methylcellulose cultures, 
and the proportion of GFP-expressing (versus non-expressing) CFU-Mix colonies 
(Figure 11, a) was counted.  
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Figure 11. Hematopoietic reconstitution was evaluated by the proportion of fluorescent (i.e. 
transgenic) versus non-fluorescent (i.e. non-transgenic, from cotransplanted supporting bone 
marrow) CFU-Mix type (panel a) obtained from in vitro clonogenic assays of the bone marrow of 
transplanted mice. Note the intense fluorescence of the CFU-Mix type colony, versus the complete 
absence of fluorescence of the adjacent mature myeloid colony. FACS analysis of the same marrow 
(panel b) shows excellent agreement of the results with those obtained by colony assays. The 
negative bone marrow sample (panel b, right side) did not yield any fluorescent CFU-Mix, whereas 
the positive sample (panel b, left) yielded 87% fluorescent CFU-Mix type colonies. 
 
Previous work has shown that over 90% of CFU-Mix colonies from the transgenic 
line used here express GFP, thus the proportion of fluorescent CFU-Mix colonies is 
expected to faithfully reflect the level of reconstitution of the bone marrow by GFP 
transgenic versus non-transgenic co-transplanted cells. Second, bone marrow from 
the transplanted mice was analysed by FACS for GFP expression. In general a high 
level of reconstitution as measured by colony assays (over 90% of fluorescent 
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colonies) was paralleled by a high level of fluorescent cells in the bone marrow (25-
35%) (Figure 11, b). 
The results of these experiments are shown in Table1 and Figure 12: both fetal liver 
and bone marrow GFPhigh cells are much more enriched in BFU-Es and (in the case 
of bone marrow) CFU-Mix than GFPint cells (Table 1). 
 
Table 1. Hematopoietic precursors in the sorted cell fractions 
 
a) bone marrow 
cell fraction BFU-E CFU-Mix Tot Myel 
 CFUx10-4cells CFUx10-4cells CFUx10-4cells
    
GFPhigh/Kit+  145 (82%)  233 (72%)  330 (37%) 
GFPint/Kit+  32 (18%)  91 (28%)  574 (63%) 
GFPint/Kit¯   -   -    - 
GFP¯/Kit-   -   -    - 
        
 
b) fetal liver 
cell fraction BFU-E CFU-Mix Tot Myel 
 CFUx10-4cells CFUx10-4cells CFUx10-4cells
    
GFPhigh/Kit+  46 (79%)  25 (53%)  134 (64%) 
GFPint/Kit+  53 (21%)  96 (47%)  283 (33%) 
GFPint/Kit¯   -   -    - 
GFP¯/Kit¯   -   -    - 
        
 
Numbers of different progenitors were evaluated in duplicate plates. The figures shown in the first 
column represent progenitor number/10^4 cells. Figures between parentheses represent the 
proportion of each progenitor that is contained in the cell fraction tested, calculated on the basis of 
numbers of cells present in each sorted fraction (see Figure 7 and 10), multiplied by the progenitor 
numbers/10^4 cells obtained in the present experiment. 
 
In striking contrast, GFPint cells are the only fetal liver cells capable of long term 
hematological reconstitution, and bone marrow GFPint cells are much more 
enriched in HSC than GFPhigh cells (Figure 12, panels a and b). 
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Figure 12. Hematopoietic progenitors and HSC content of cell fractions expressing different levels 
of GFP.  
BM long term repopulation by cell fractions from bone marrow (a) and FL (b). Reconstitution was 
evaluated by the proportion of GFP¯expressing CFU-Mix type colonies obtained from the bone 
marrow of each transplanted mouse; GFP– colonies are assumed to derive from non-transgenic stem 
cells contained in the support bone marrow co-transplanted with the FACS-fractionated transgenic 
cells. 90-100% of CFU-Mix type colonies from untreated Kit/GFP mice express GFP (Cairns et al., 
2003). The number of cells used for each transplant is shown. The data for the transplantation of 
fetal liver cells refer to an experiment using cells pooled from 16 GFP+ livers (5 pregnant females) at 
E12.5. The data for bone marrow are from four adult donor transgenic mice. Recipient mice 
surviving at the time of analysis were 1-4 for each experimental point. 
 
Thus, the Kit+/GFPint fraction is specifically enriched in HSC versus committed 
progenitors.  
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4.2 Kit/GFP bone marrow derived cells can generate Kit/GFP+ cardiac stem 
cells in damaged heart 
In collaboration with Dr. Elisa Messina group at Università "La Sapienza" we 
decided to utilize the Kit/GFP transgenic model, that we demonstrated to represent 
a reliable model for the stem cell marker Kit regulation, to address the question of 
whether, following myocardial infarction, bone marrow cells contribute to 
regeneration of a functional Kit+ cardiac stem cells (CSCs) population. Indeed, it 
was previously reported Messina et al showed that it is possible to grow in vitro 
large numbers of human and murine CSCs, which transiently express Kit and 
generate clonal “cardiospheres” (CSs), capable of cardiac differentiation (Messina 
et al., 2004; Smith et al., 2007).  
CSs are a kind of microtissue, which spontaneously express cardiac markers in a 
minority of cells and occasionally show synchronous beating. They may be induced 
to (in vitro and in vivo) cardiomyocyte differentiation, and engraft the heart, 
inducing functional improvement after injection at the border zone of a myocardial 
infarction (MI) (Messina et al., 2004). CS formation may be shown to be clonal 
under appropriate conditions. The cell giving rise to the CS is proposed to be a Kit+ 
precursor, based on immunofluorescent analysis with anti-Kit antibodies and 
studies on CS-forming cardiac cells using Kit/GFP transgenic mice (Messina et al., 
2004).  
 
4.2.1 Bone marrow-derived cells are able to generate cardiospheres in vitro 
 
To better characterize the Kit/GFP transgenic mouse as a model for cardiac 
regeneration studies, we investigated if cells derived from bone marrow of Kit/GFP 
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mice can give rise to Kit/GFP+ CSCs, by transplanting total bone marrow from 
Kit/GFP transgenic mice into lethally irradiated wild type mice (Figure 13).  
 
Figure 13: Schematic representation of the experimental design. 
 
After four months, a subset of the recipient mice was subjected to MI, and after 
two-three additional weeks mice with or without MI were sacrificed. Bone marrows 
and hearts from these mice were explanted and grown in vitro. Bone marrow cells 
were isolated and cultured in clonogenic assays to assess the hematological 
reconstitution of the recipients by the donor cells. All the analyzed mice had normal 
levels of hematopoietic progenitors (Figure 14, a), and a high percentage of the 
hematopoietic colonies were GFP positive (Figure 14, b), indicating that all the 
animals were fully reconstituted by the transplanted Kit/GFP BM. 
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Figure 14: Hematopoietic reconstitution of Kit/GFP bone marrow-transplanted mice  
The hematopoietic reconstitution of mice transplanted with Kit/GFP bone marrow was assessed after 
four months using clonogenic assays. a) Hematopoietic precursors in donor and transplanted mice, 
b) Percentage of reconstitution in the transplanted mice, as assessed by the percentage of fluorescent 
CFU-Mix colonies, c) Example of fluorescent CFU-Mix colony (left, bright field; right, 
fluorescence). 
 
In parallel, isolated myocardial tissues were cultured as explants and after 1-4 
weeks an adherent layer of fibroblast-like cells was formed and small, phase-bright 
cells migrated on top of it. These phase-bright cells were then plated in a culture 
medium supporting the formation of CSs (Figure15) and isolation of the CS-
forming cells could be performed at least 4 times at 6- to 10-day intervals from the 
same explant. 
 65
 
 
 
 
 
Figure 15: Kit/GFP positive CS and CS-forming-cells. 
a) Kit/GFP positive CS-forming cells were collected from the explant of infarcted heart 13 days 
after the beginning of the culture, and plated onto poly-D-lysine for 1 day to allow CS formation. 
Note the initial appearance of slightly fluorescent cells; b) Fully formed mouse CS on day 20, 7 days 
after collection of CS-forming cells. Strong green fluorescence from transgenic Kit/GFP expression 
is predominantly in the center of the sphere, and declines at the periphery, where some 
differentiation spontaneously initiates; c) PCR analysis of Kit/GFP presence in genomic DNA 
extracted from single CSs. 351-441 indicate different transplanted-infarcted mice; LD, sizemarker; 
C+a and C+b represent internal positive controls (genomic DNA from 10^7 and 10^6 Kit/GFP BM); 
WT, genomic DNA from 10^7 wild type BM cells; PCR-, negative control on PCR mix. Product of 
amplification from sample 438 was confirmed by in vitro automatic sequencing (not shown). 
 
Once formed, primary CSs (5-10/heart) were collected and subjected to an 
amplification step (Smith et al., 2007), by growing them as adherent cells for one 
c 
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month, and subsequently transferred back onto poly-D-lysine-coated plates to 
generate large numbers of secondary CSs for analysis.  
Efficient cell growth and CS formation was achieved in 6/9 mice with MI, but not 
in any of the mice not subjected to MI. During culture, at the fibronectin stage, very 
few cells expressed GFP, as expected from previous results obtained using Kit/GFP 
transgenic heart (Messina et al., 2004); however, all CSs that developed in poly-D-
lysine (whether primary or secondary) were clearly GFP positive, showing a 
majority of Kit/GFP+ cells (Figure 15, b). PCR confirmed the presence of the GFP 
transgene in all of them (Figure 15, c). 
 
4.2.2 Cells from Kit/GFP bone marrow-derived CS express cardiac markers  
 
CSs apparently grow by progressive expansion of a central core of immature cells, 
which occasionally initiate differentiation at the periphery of the sphere (Messina et 
al., 2004). In agreement with this observation, CSs derived from bone marrow-
transplanted cells are intensely fluorescent in the center, and show a rim of dim or 
non-fluorescent cells at the periphery (Figure 15, b); this is expected, as 
differentiated cardiac cells do not express Kit. To better characterize the cells 
present in a CS, we stained individual CS with antibodies against Nkx2.5, a 
transcription factor representing a relatively early cardiac marker, or with Troponin 
I, a later cytoplasmic marker, and we evaluated both antibody staining and GFP 
fluorescence. Confocal analysis, conducted by our collaborators Dr. Lucio Barile 
and Dr. Laura Spinardi, shows that a small number of cells, mainly at the periphery 
of the sphere, express these markers, singly or in combination with a low level of 
GFP (Figure 16 and Figure 17). 
 67
 
 
Figure 16: CS and CSDCs Phenotypes. 
Fluorescence confocal analysis of a CS, derived from the infarcted heart of a lethally-irradiated 
mouse transplanted with marrow cells of Kit/GFP transgenic mice a) Merged image showing 
coexpression in some cells of donor cell-derived GFP (green) and Nkx 2.5 (an immature cardiac 
cell-specific transcription factor) (red); nuclei are stained blue by Hoechst dye aI) Panel 
demonstrating co-localization of Kit/GFP and Nkx 2.5. aII-aIII-aIV) View of single fluorescence 
channels. b-c) Single cells derived from CS dissociation, demonstrating nuclear co-localization of 
GFP and Nkx 2.5. 
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Figure 17: Cardiospheres. 
Fluorescence confocal analysis of a cardiosphere, derived from the infarcted heart of a lethally-
irradiated mouse transplanted with marrow cells of Kit/GFP transgenic mice a) Cardiosphere 
expressing GFP throughout its core (green) and cTnI (a differentiated cytoplasmic cardiac cell 
marker) (red) on its periphery. aI-aII) Cardiosphere confocal panels showing the expressions of cTnI 
mainly localized on the surface.  
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This suggests that cells, which occasionally commit to cardiomyocyte 
differentiation, progressively extinguish Kit/GFP expression, while upregulating 
cardiac-specific genes. Importantly, this result indicates that bone marrow-derived 
cells present in the CS may express cardiac markers. 
 
4.2.3 BM-derived CSs are capable of cardiac regeneration in vivo 
 
We next asked whether Kit/GFP+ CSs were functionally capable of regeneration in 
vivo. As GFP expression is expected to be repressed and lost following full cardiac 
differentiation, to monitor the fate of CS-derived cells (CSDCs) we transduced 
them in vitro with a lentiviral vector expressing the E.coli β-galactosidase gene. 
1x105 labelled cells were then injected in the border zone of three wild type mice, 
immediately after MI had been induced. Three additional MI mice (as controls) 
were injected with PBS. The animals were sacrificed three weeks later and 
cryosections of the hearts analyzed by hystochemical and immunohystochemical 
techniques. 
The injected cells, identified by their blue nuclear staining (Figure 18 CI-CII), show 
essentially the same in vivo features as those previously described (Messina et al., 
2004; Smith et al., 2007) when injected in the same conditions, at least in term of 
pattern of distribution and differentiation. In fact, many blue stained CSDCs could 
be found engrafted throughout the infarct region of the mouse heart at 20 days 
(Figure 18), and a high proportion of them could be identified as differentiated 
cardiomyocytes (Figure 18, a) and vascular cells (Figure 18, b) within viable 
myocardium and in scattered islands in the infarct area. 
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Figure18: Engraftment and Differentiation of CSDCs. 
 Fluorescence confocal analyses of infarcted heart section of a wild type mouse, 20 days after 
injection of β-galactosidase (β-Gal)-labelled cells from GFP-positive cardiospheres obtained from 
hearts of Kit/GFP marrow- transplanted mice (as in Fig.4); 
a) low magnification picture of the CSDCs [identified with a primary antibody against nuclear β-
galactosidase (β-Gal), (red)] that are present in the transmural infarct, within and together cellular 
elements expressing Myosin Heavy Chain (MHC, green) in the regenerating area; aI) higher 
magnification views of picture shown in panel a: co-localization of β-Gal-positive CSDCs and 
viable myocardium. The arrows indicate the sarcomeric structure in the cells that are double positive 
for β-Gal (red) and MHC (green); aII-aIV ) Same picture showing the nuclear β-Gal expression (aIII), 
the corresponding Hoechst labelling (arrows) (aII) and (aIV ) the MHC green fluorescence from the 
inset in a (continues in the following page) 
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b) nuclear β-Gal (green)-expressing CSDCs, double labeled for Smooth Muscle Actin (SMA, red), 
are shown within the vessels walls (arrows) in the context of the infarcted area; bI-bIII) Single 
fluorescent channels view of cells indicated in panel b: the β-Gal-stained nuclei (green) correspond 
to the Hoechst-labelling (blue) in the same cells.  
c) Hematoxylin/eosin and β-Gal (blue) hystochemical staining of criosections from one of the 
infarcted hearts, explanted 20 days after CSDCs injection: engraftment of the β-Gal (blue) stained 
CSDCs is shown. Blue-labeled nuclei are present both into the Hematoxylin/eosin stained and un-
stained cells, in the context of the infarcted area. cI-cII) Engraftment of CSDCs is depicted 20 days 
after injection in infarcted heart sections stained for β-Gal. 
 
Islands of myocardial regeneration found within the infarct zone in the CSDC-
injected mice (but not in the control treated animals) may be related to a direct 
regenerative effect and/or to a paracrine action leading to increased mobilization of 
endogenous cardiac stem cells. 
 
4.2.4 Analysis of CSs for hematopoietic potential 
 
We also investigated whether hematopoietic progenitors, known to express Kit, 
might be present within the population of GFP+ cells of CSs. We used two 
approaches. Firstly, we grew BM cells from wild type untreated or transplanted-MI 
mice in the culture conditions used for CS formation. Bone marrow cells from 2 
untreated and 5 transplanted-MI mice were plated in fibronectin-coated dishes and 
after two days transferred to poly-D-lysine-coated multiwell plates. The cultures, 
scored over a period of one month did not show any CS-like clones, but rather 
exhibited the morphological characteristics of mesenchymal cells, as shown in 
Figure 19. 
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Figure 19: In vitro bone marrow cells cultured in CS supporting medium  
Bone marrow cells were cultured following the culture protocol used to obtain cardiospheres from 
heart explants. No sphere-like aggregates were obtained after culture in poly-D-lysine, while 
mesenchymal-like monolayers were observed (left, 100X; right, 200X) 
 
Second, we plated CS cells, from either fibronectin- or poly-D-lysine-coated 
cultures, in clonogenic assays used for the evaluation of hematopoietic progenitors. 
Cultures were scored at various time points, but in no instance could hematopoietic 
colonies be detected (data not shown).  
Finally, we analyzed CSs to verify whether they might harbour hematopoietic stem 
cells, capable of long-term bone marrow reconstitution. For this purpose we used 
pools of CSs derived from Kit/GFP transgenic newborn mice, as a large number of 
cells was required to be transplanted into lethally irradiated recipients. The recipient 
animals, together with CS cells, also received small numbers of wild type bone 
marrow cells as support. As shown in Figure 19 none of the reconstituted mice had 
CS-derived BM cells, not even those transplanted with 10^6 CS cells, as assessed 
by PCR analysis. Thus we conclude that CSs do not seem to have hematopoietic 
potential. 
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Figure 20: Analysis of CSC hematopoietic potential  
a) Schematic representation of the experimental procedure adopted to test the hematopoietic 
potential of CSC. b) PCR on genomic DNA extracted from 10^7 bone marrow cells of each 
transplanted mouse 4 months after receiving a transplant of cardiosphere cells from the heart of 
Kit/GFP transgenic mice: none of the recipient animals (labelled from 422 to 436) showed the 
presence of Kit/GFP construct (C+, positive control; wt, untransplanted wt mouse). 
 
 
 
 
 74
5. DISCUSSION 
 
In a previous study we generated a Kit transgene capable of driving GFP expression 
in progenitor cells both of the germ and the hematopoietic cell lineages. In this 
work we report that this transgene is efficiently expressed in fetal liver and adult 
bone marrow HSC, thus providing a powerful in vivo model to monitor the 
expression and regulation of a gene critical for the transduction of essential signals 
in several stem/progenitor cell types. In addition, our findings unexpectedly show 
that the level of transgene expression discriminates between HSC (intermediate 
level GFP-expressors) and other progenitors, such as BFU-E and CFU-Mix (mostly 
high level GFP-expressors). The present results, together with other reports, now 
indicate that this transgene is expressed in a variety of stem cells, ranging from 
Primordial Germ Cells to cardiac and hematopoietic stem cells, providing the basis 
for the elucidation of DNA sequences regulating a stem cell gene in multiple stem 
cells. 
 
5.1 Transgenic Kit/GFP expression in hematopoietic Kit+ cells. 
 
The Kit transgene is efficiently expressed in Kit+ cells, as over 90% of Kit+ cells in 
fetal liver and bone marrow are also GFP+. In contrast, Kit¯ cells are either negative 
for GFP expression, or express GFP at average levels significantly lower than Kit+ 
cells (Figure 3, Figure 5, Figure 7 and Figure 10). We interpret these results as 
indicating that the transgene begins to be efficiently transcribed in early Kit+ 
progenitors, and is then downregulated when progenitors initiate differentiation, 
switch off Kit transcription, and progressively turn-over Kit mRNA and protein. 
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This interpretation assumes that the stability of GFP mRNA and protein is higher 
than that of Kit mRNA and protein. This is plausible, as GFP is known to be a 
rather stable molecule whereas Kit is a membrane protein subject to active 
internalization, ubiquitination and degradation upon binding to SCF (Broudy, 
1997; Corish and Tyler-Smith, 1999; Moriyama et al., 1996). An alternative 
explanation is that a low level expression of the transgene may persist in some cells 
that have already extinguished endogenous Kit transcription, as the present Kit 
transgene consists of only a subset of potential regulatory elements of the large Kit 
gene (Cairns et al., 2003; Besmer et al., 2006). Although we cannot completely 
rule out this possibility, the correct downregulation of Kit/GFP in myelomonocytic 
cells grown in vitro (Cai et al., 2004) suggests that our transgene includes critical 
sequences required to faithfully recapitulate endogenous Kit expression.  
 
5.2 GFP expression levels in Kit+ cells discriminate between HSC and 
progenitors 
 
Kit+ cells in fetal liver and bone marrow express different levels of GFP, as 
assessed by flowcytometric analysis, and have been sorted into three fractions: a 
negative, an intermediate and a high fluorescence fraction. Transplantation 
experiments of fetal liver and bone marrow Kit+ cells of different GFP fluorescence 
clearly show that the GFPint population is highly enriched in HSC relative to the 
GFPhigh population, whereas the reverse is true for progenitors such as BFU-E and 
CFU-Mix. Taking into account the relative proportions of GFPint and GFPhigh cells, 
a large majority of BFU-E and (in bone marrow only) CFU-Mix are detected in the 
GFPhigh population (Table 1). There are several possible explanations accounting 
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for the differential expression of the Kit/GFP transgene in different stem/progenitor 
cell types. First, this phenomenon might be related to low cycling activity of HSC 
versus progenitors, a well established fact for adult HSC, that was recently 
confirmed in fetal liver HSC as well (Nygren et al., 2006). It is possible that slowly 
cycling HSC need lower levels of Kit than progenitors, and thus a lower 
transcriptional output. Alternatively, even if similar levels of membrane Kit were 
needed for HSC and progenitors, the latter cells, being highly stimulated by SCF, 
might have a faster turnover of membrane Kit than HSC, and would thus require a 
higher Kit transcription level, in order to maintain the appropriate level of the SCF 
receptor Kit. If either of these hypotheses were correct, we would expect the 
Kit/GFP transgene to be more expressed in progenitors than in HSC. 
Phenotypic profiles of the selected populations of fetal liver and bone marrow cells 
confirm that the level of GFP expression effectively discriminates between different 
immunophenotypes. In fact, most of the CD11b+/Kit+/Sca1+ positive cells (a 
phenotype that is consistent with that of fetal liver HSC) are contained within the 
fetal liver GFPint population, whereas the large majority of the Kit+ cells in the GFP 
high population are CD11b¯/Sca1¯ (Figure 5 and Figure 6). Thus, the fetal liver 
HSC immunophenotype is highly correlated to the transplantation results obtained 
using the Kit+/GFPint subset. Similarly, in adult bone marrow (Figure 8 and Figure 
9), the tip of the SP, known to be highly enriched in stem cells, is enriched in 
Kit+/Sca1+/GFPint cells relative to the HSC-poor upper SP, that mainly contains 
Kit+/Sca1¯/GFPhigh cells, again stressing the correlation of low GFP expression 
with HSC immunophenotype and transplantation properties.  
To our knowledge, there are few in vivo systematic studies investigating the 
correlation, if any, of Kit levels with HSC properties. Expression of Kit is 
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considered an essential characteristic of HSC; however, cells expressing very low 
levels of Kit mRNA and little or no membrane Kit protein have been shown to be 
able to give efficient long term reconstitution (Doi et al., 1997; Klarmann et al., 
2003; Kotton et al., 2005); in one experiment, these cells were able to develop in 
vitro into Kit+ cells capable of long-term in vivo hematopoietic reconstitution. Thus, 
there may be “dormant” Kitlow/¯ HSC, able to generate, upon appropriate 
stimulation, the “classical” Kit+ HSC. These rare Kitlow/- HSCs would probably 
express GFP at low levels, but may have escaped detection in our transplantation 
experiments because they are “diluted” by the large excess of Kit¯ cells. 
On the other hand, it was shown by in vitro studies that primitive hematopoietic 
progenitors in cell cycle dormancy are Kitlow, whereas actively cell cycling 
progenitors are Kit high (Katayama et al., 1993). Taking together our own results 
with these previous data, we suggest that the transgenic GFP level in Kit+ cells 
might highlight the existence of a low level Kit transcriptional program in HSC and 
immediately downstream progenitors, as opposed to a high level transcriptional 
program of committed myeloid progenitors, such as CFU-Mix, BFU-E, etc. 
Consistently with this hypothesis, it has been reported that Common Lymphoid 
Progenitor (CLP), a progenitor of both T and B lymphocytes that lies immediately 
downstream to the HSC, expresses low levels of Kit (Kondo et al., 1997). In this 
view, the expression pattern of Kit would be similar to the expression pattern of 
other stem/progenitor cell markers, such as CD34 and Thy1.  
There are only few transgenic constructs known to be efficiently expressed in HSC; 
these are based on regulatory sequences corresponding to genes encoding 
transcription factors such as SCL/Tal1 (Sanchez et al., 2001; Silberstein et al., 
2005), and possibly GATA-2 (Kobayashi-Osaki et al., 2005) and the membrane 
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proteins Sca1 and CD34 (Ma et al., 2002; Okuno et al., 2002). As SCL/Tal1 and 
GATA-2 are both potential regulators of Kit, and Sca1 and CD34 are coexpressed 
with it, comparison and identification of common regulatory motifs between these 
genes may help to define a critical regulatory network of gene expression in HSC. 
The DNA sequences necessary for Kit transcription in hematopoietic cells are 
represented by approximately 8 Kb of the 5’ part of the first intron, in addition to 
the promoter (by itself inactive)(Cairns et al., 2003). Important regulatory 
sequences are contained in the most 5’ 4 Kb of the intron, that is sufficient (with the 
promoter) for transgenic hematopoietic expression; however, the further addition of 
4Kb of more 3’ intron sequences, to yield the full construct, seems to better repress 
Kit/GFP activity in myeloid colonies developing in vitro from transgenic 
progenitors (Cairns et al., 2003). This effect might, in part, be due to a GATA 
binding site in the DNAse1 Hypersensitive Site 5, that represses Kit transcription 
when bound by GATA-1 (Munugalavadla et al., 2005). 
 
5.3 The Kit/GFP construct is expressed in multiple stem cell types.  
 
Different types of stem cells may express a number of common transcription factors 
and signalling molecules, for example, Bmi1 and Notch1 in both HSC and neural 
stem cells (Molofsky et al., 2003; Park et al., 2003; Androutsellis-Theotokis et al., 
2006; Moore and Lemischka, 2006), which are responsible for a subset of stem cell 
properties, together with more cell type-specific stem cell genes. The Kit gene 
provides a significant example of such a widely acting stem/progenitor cell gene. 
Indeed, loss of function mutations in the Kit locus affect diverse cell lineages and 
result in a range of phenotypes, including anemia, sterility, defective pigmentation, 
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mast cell deficits, lack of interstitial cells of Cajal, defects in peripheral nerve 
regeneration and spatial learning memory deficits, pointing at Kit as a pleiotropic, 
though cell-type restricted, molecule. Therefore, it would be particularly relevant to 
have a mouse model in which the transgene efficiently recapitulates the activity of 
the endogenous molecule. We previously reported that the Kit/GFP transgene is 
highly expressed in Primordial Germ Cells and in hematopoietic progenitors 
(Cairns et al., 2003). Here we show that it is efficiently transcribed also in HSC 
and recent studies indicate that the transgene is also active in early blastocysts 
grown in vitro, and in ES cells (unpublished observations of S.O, L.C and Dr. 
Susanna Dolci, September 2006). Finally, we and others showed that the same 
transgene is expressed in a population of cardiac stem (Messina et al., 2004; 
Cerisoli et al., 2007b). Indeed, taking advantage of the transgene expression both in 
HSC and in CSCs we investigated the trafficking between bone marrow and heart 
following infarction. 
The rationale for our experimental strategy is that resident CSC are Kit+ (Beltrami 
et al., 2003) and that Kit/GFP+ cells from the heart of Kit/GFP transgenic mice 
have been shown to participate in CSs formation in vitro (Messina et al., 2004). 
Thus, if CS cells from mice transplanted with marrow from transgenic mice show 
GFP positivity, they must derive from the bone marrow; furthermore, GFP 
expression from these cells may represent the activation of a CSC transcriptional 
program (Messina et al., 2004). 
GFP expression from the transgene is known to be very selective (Cairns et al., 
2003; Cerisoli et al., 2007a), being limited to the appropriate cell types in the 
gonads (PGC) and in the hematopoietic system (stem cells and early progenitors). 
Noteworthy, in our experiments, all CSs that grew from the hearts of transplanted 
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(and infarcted mice) showed GFP fluorescence and in all CSs observed, the 
majority of the cells were GFP positive (Figure 15). This result indicates that 
endogenous CSC were virtually absent in the heart of these mice; if any 
endogenous CSC had still been present, we should have seen at least some CS 
consisting entirely or predominantly of unlabeled cells. Consistent with this result, 
explants from Kit/GFP bone marrow transplanted mice that had not undergone MI, 
did not give rise to any CSs. It is well known (Fazel et al., 2006) that infarction 
mobilizes and recruits into the heart a variety of bone marrow cells; on the other 
hand, the irradiation necessary for bone marrow transplantation may likely have 
killed most endogenous CSC. In addition, the MI might also stimulate the 
proliferation of CSCs that had migrated to the heart. Thus, we interpret these results 
to signify that, in CSC-deficient irradiated mice, the heart is repopulated, following 
infarction, with bone marrow cells, which develop as Kit/GFP+ CS-forming cells. It 
is largely accepted that the bone marrow harbours different kinds of stem and 
progenitor cells, such as hematopoietic, endothelial and mesenchymal cells. At 
present, the identity of the bone marrow-derived cell type responsible for CSC 
regeneration still remains an open question. Our results, however, provide evidence 
that CSs do not contain hematopoietic stem or progenitor cells as such: first, bone 
marrow cells grown in vitro under conditions appropriate for CS formation do not 
give rise to any CS-like aggregate; second, even large numbers of cells derived 
from CSs are not capable of in vitro colony formation or in vivo bone marrow 
reconstitution, upon transplantation. 
Thus, bone marrow-derived cells that give rise to CS are likely to be of a non-
hematopoietic cell type; alternatively, cells belonging to the hematopoietic system 
might have assumed “new” biological properties in the heart environment, that 
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allow them to self renew as CSC and to differentiate into mature cardiomyocytes, 
both spontaneously and following induction in appropriate conditions.  
Our transgenic mouse lines provide a powerful tool to shed light on the function of 
the Kit receptor tyrosine kinase in the properties of different types of normal and, 
possibly, tumor stem cells. Furthermore, our present results, together with those 
reported (Cairns et al., 2003; Messina et al., 2004)suggest the hypothesis that Kit 
might be regulated by subsets of common transcriptional programs in different stem 
cells. Targets of the responsible transcription factors must lie within the relatively 
short regions encompassed by our transgene. 
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6. CONCLUSIONS 
 
Our results show that, in our Kit/GFP transgenic model, GFP expression 
recapitulates the endogenous expression patterns of Kit. Indeed, on the basis of 
Kit/GFP construct expression in Kit+ cells it is possible to discriminate between 
different hematopoietic stem and/or progenitor cell populations. 
 
In addition, given the peculiar role of Kit in multiple types of stem cells, we 
demonstrated the existence of a contribution of BM-derived cells to the Kit/GFP+ 
cardiac stem cell pool regeneration after myocardial infarction. 
 
These evidences, together with previous results, reinforce the idea that the Kit/GFP 
transgenic model can be regarded as a powerful tool for the study of differentiation 
dynamics of normal and pathological tissues in which the Kit/SCF pathway exherts 
a fundamental regulative role.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83
7. REFERENCE LIST 
 
Abkowitz,J.L., Robinson,A.E., Kale,S., Long,M.W., and Chen,J. (2003). 
Mobilization of hematopoietic stem cells during homeostasis and after cytokine 
exposure. Blood 102, 1249-1253. 
Adams,G.B., Chabner,K.T., Alley,I.R., Olson,D.P., Szczepiorkowski,Z.M., 
Poznansky,M.C., Kos,C.H., Pollak,M.R., Brown,E.M., and Scadden,D.T. (2006). 
Stem cell engraftment at the endosteal niche is specified by the calcium-sensing 
receptor. Nature 439, 599-603. 
Akashi,K., Traver,D., Miyamoto,T., and Weissman,I.L. (2000). A clonogenic 
common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 
193-197. 
Al Hajj,M., Wicha,M.S., Benito-Hernandez,A., Morrison,S.J., and Clarke,M.F. 
(2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. 
Acad. Sci. U. S. A 100, 3983-3988. 
Anderson,D.M., Lyman,S.D., Baird,A., Wignall,J.M., Eisenman,J., Rauch,C., 
March,C.J., Boswell,H.S., Gimpel,S.D., Cosman,D., and . (1990). Molecular 
cloning of mast cell growth factor, a hematopoietin that is active in both membrane 
bound and soluble forms. Cell 63, 235-243. 
Androutsellis-Theotokis,A., Leker,R.R., Soldner,F., Hoeppner,D.J., Ravin,R., 
Poser,S.W., Rueger,M.A., Bae,S.K., Kittappa,R., and McKay,R.D. (2006). Notch 
signalling regulates stem cell numbers in vitro and in vivo. Nature 442, 823-826. 
Arai,F., Hirao,A., Ohmura,M., Sato,H., Matsuoka,S., Takubo,K., Ito,K., Koh,G.Y., 
and Suda,T. (2004). Tie2/angiopoietin-1 signaling regulates hematopoietic stem 
cell quiescence in the bone marrow niche. Cell 118, 149-161. 
Asakura,A., Seale,P., Girgis-Gabardo,A., and Rudnicki,M.A. (2002). Myogenic 
specification of side population cells in skeletal muscle. J. Cell Biol. 159, 123-134. 
Avecilla,S.T., Hattori,K., Heissig,B., Tejada,R., Liao,F., Shido,K., Jin,D.K., 
Dias,S., Zhang,F., Hartman,T.E., Hackett,N.R., Crystal,R.G., Witte,L., 
Hicklin,D.J., Bohlen,P., Eaton,D., Lyden,D., de Sauvage,F., and Rafii,S. (2004). 
Chemokine-mediated interaction of hematopoietic progenitors with the bone 
marrow vascular niche is required for thrombopoiesis. Nat. Med. 10, 64-71. 
Beghini,A., Tibiletti,M.G., Roversi,G., Chiaravalli,A.M., Serio,G., Capella,C., and 
Larizza,L. (2001). Germline mutation in the juxtamembrane domain of the kit gene 
in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 
92, 657-662. 
Bellantuono,I. (2004). Haemopoietic stem cells. Int. J. Biochem. Cell Biol. 36, 607-
620. 
 84
Beltrami,A.P., Barlucchi,L., Torella,D., Baker,M., Limana,F., Chimenti,S., 
Kasahara,H., Rota,M., Musso,E., Urbanek,K., Leri,A., Kajstura,J., Nadal-
Ginard,B., and Anversa,P. (2003). Adult cardiac stem cells are multipotent and 
support myocardial regeneration. Cell 114, 763-776. 
Berenson,R.J., Andrews,R.G., Bensinger,W.I., Kalamasz,D., Knitter,G., 
Buckner,C.D., and Bernstein,I.D. (1988). Antigen CD34+ marrow cells engraft 
lethally irradiated baboons. J. Clin. Invest 81, 951-955. 
Bernex,F., De Sepulveda,P., Kress,C., Elbaz,C., Delouis,C., and Panthier,J.J. 
(1996). Spatial and temporal patterns of c-kit-expressing cells in WlacZ/+ and 
WlacZ/WlacZ mouse embryos. Development 122, 3023-3033. 
Bernstein,A., Forrester,L., Reith,A.D., Dubreuil,P., and Rottapel,R. (1991). The 
murine W/c-kit and Steel loci and the control of hematopoiesis. Semin. Hematol. 
28, 138-142. 
Bernstein,B.E., Mikkelsen,T.S., Xie,X., Kamal,M., Huebert,D.J., Cuff,J., Fry,B., 
Meissner,A., Wernig,M., Plath,K., Jaenisch,R., Wagschal,A., Feil,R., 
Schreiber,S.L., and Lander,E.S. (2006). A bivalent chromatin structure marks key 
developmental genes in embryonic stem cells. Cell 125, 315-326. 
Bertrand,J.Y., Giroux,S., Golub,R., Klaine,M., Jalil,A., Boucontet,L., Godin,I., and 
Cumano,A. (2005). Characterization of purified intraembryonic hematopoietic stem 
cells as a tool to define their site of origin. Proc. Natl. Acad. Sci. U. S. A 102, 134-
139. 
Besmer,E., Market,E., and Papavasiliou,F.N. (2006). The transcription elongation 
complex directs activation-induced cytidine deaminase-mediated DNA 
deamination. Mol. Cell Biol. 26, 4378-4385. 
Besmer,P., Murphy,J.E., George,P.C., Qiu,F.H., Bergold,P.J., Lederman,L., 
Snyder,H.W., Jr., Brodeur,D., Zuckerman,E.E., and Hardy,W.D. (1986). A new
acute transforming feline retrovirus and relationship of its oncogene v-kit with the 
protein kinase gene family. Nature 320, 415-421. 
 
Bhardwaj,G., Murdoch,B., Wu,D., Baker,D.P., Williams,K.P., Chadwick,K., Ling,L.E., 
Karanu,F.N., and Bhatia,M. (2001). Sonic hedgehog induces the proliferation of 
primitive human hematopoietic cells via BMP regulation. Nat. Immunol. 2, 172-180. 
 
Bhatia,M., Wang,J.C., Kapp,U., Bonnet,D., and Dick,J.E. (1997). Purification of 
primitive human hematopoietic cells capable of repopulating immune-deficient mice. 
Proc. Natl. Acad. Sci. U. S. A 94, 5320-5325. 
 
Bjerknes,M. and Cheng,H. (1999). Clonal analysis of mouse intestinal epithelial 
progenitors. Gastroenterology 116, 7-14. 
 
Blair,A., Hogge,D.E., Ailles,L.E., Lansdorp,P.M., and Sutherland,H.J. (1997). Lack 
of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term 
proliferative ability in vitro and in vivo. Blood 89, 3104-3112.  
 85
Blair,A., Hogge,D.E., and Sutherland,H.J. (1998). Most acute myeloid leukemia 
progenitor cells with long-term proliferative ability in vitro and in vivo have the 
phenotype CD34(+)/CD71(-)/HLA-DR-. Blood 92, 4325-4335. 
Blair,A. and Sutherland,H.J. (2000). Primitive acute myeloid leukemia cells with 
long-term proliferative ability in vitro and in vivo lack surface expression of c-kit 
(CD117). Exp. Hematol. 28, 660-671. 
Bolognia,J.L. and Pawelek,J.M. (1988). Biology of hypopigmentation. J. Am. 
Acad. Dermatol. 19, 217-255. 
Bonnet,D. (2002). Haematopoietic stem cells. J. Pathol. 197, 430-440. 
Bonnet,D. and Dick,J.E. (1997). Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737. 
Boyer,L.A., Plath,K., Zeitlinger,J., Brambrink,T., Medeiros,L.A., Lee,T.I., 
Levine,S.S., Wernig,M., Tajonar,A., Ray,M.K., Bell,G.W., Otte,A.P., Vidal,M., 
Gifford,D.K., Young,R.A., and Jaenisch,R. (2006). Polycomb complexes repress 
developmental regulators in murine embryonic stem cells. Nature 441, 349-353. 
Broudy,V.C. (1997). Stem cell factor and hematopoiesis. Blood 90, 1345-1364. 
Bruce,W.R. and van der Gaag (1963). A quantitative assay for the number of  murine 
limphoma cells capable of proliferation in vivo. Nature 199, 79-80. 
 
Buehr,M., McLaren,A., Bartley,A., and Darling,S. (1993). Proliferation and migration 
of primordial germ cells in We/We mouse embryos. Dev. Dyn. 198, 182-189. 
 
Bunting,K.D. (2002). ABC transporters as phenotypic markers and functional 
regulators of stem cells. Stem Cells 20, 11-20. 
 
Cable,J., Jackson,I.J., and Steel,K.P. (1995). Mutations at the W locus affect 
survival of neural crest-derived melanocytes in the mouse. Mech. Dev. 50, 139-150. 
 
Cai,J., Weiss,M.L., and Rao,M.S. (2004). In search of "stemness". 
Exp. Hematol. 32, 585-598.  
 
Cairns,L.A., Moroni,E., Levantini,E., Giorgetti,A., Klinger,F.G., Ronzoni,S., 
Tatangelo,L., Tiveron,C., De Felici,M., Dolci,S., Magli,M.C., Giglioni,B., and 
Ottolenghi,S. (2003). Kit regulatory elements required for expression in developing 
hematopoietic and germ cell lineages. Blood 102, 3954-3962. 
 
Calvi,L.M., Adams,G.B., Weibrecht,K.W., Weber,J.M., Olson,D.P., Knight,M.C., 
Martin,R.P., Schipani,E., Divieti,P., Bringhurst,F.R., Milner,L.A., Kronenberg,H.M., 
and Scadden,D.T. (2003). Osteoblastic cells regulate the haematopoietic stem cell 
niche. Nature 425, 841-846.  
 86
Camargo,F.D., Chambers,S.M., and Goodell,M.A. (2004). Stem cell plasticity: 
from transdifferentiation to macrophage fusion. Cell Prolif. 37, 55-65. 
Cancelas,J.A., Lee,A.W., Prabhakar,R., Stringer,K.F., Zheng,Y., and 
Williams,D.A. (2005). Rac GTPases differentially integrate signals regulating 
hematopoietic stem cell localization. Nat. Med. 11, 886-891. 
Cancelas,J.A. and Williams,D.A. (2006). Stem cell mobilization by beta2-agonists. 
Nat. Med. 12, 278-279. 
Cerisoli, F., Cassinelli, L., Lamorte, G., Citterio, S., Bertolotti, F., Magli, M. C., 
and Ottolenghi, S. (2007a). GFP transgene driven by kit regulatory sequences is 
differentially expressed in hematopoietic stem and progenitor cells.   
In preparation  
 
Cerisoli, F., Barile, L., Gaetani, R., Chimenti, I.,  Forte, E., Frati, G., Cassinelli, L., 
Spinardi, L., Altomare, C., Kizana, E., Giacomello, A., Messina, E., Ottolenghi, S., 
and Magli, M. C. (2007b). Bone marrow derived cells can generate cardiac stem 
cells in damaged heart. Submitted
Chabot,B., Stephenson,D.A., Chapman,V.M., Besmer,P., and Bernstein,A. (1988). 
The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps 
to the mouse W locus. Nature 335, 88-89. 
Cheng,T., Shen,H., Giokas,D., Gere,J., Tenen,D.G., and Scadden,D.T. (1996). 
Temporal mapping of gene expression levels during the differentiation of individual 
primary hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A 93, 13158-13163. 
Christensen,J.L. and Weissman,I.L. (2001). Flk-2 is a marker in hematopoietic stem 
cell differentiation: a simple method to isolate long-term stem cells. Proc. Natl. 
Acad. Sci. U. S. A 98, 14541-14546. 
Corish,P. and Tyler-Smith,C. (1999). Attenuation of green fluorescent protein half-
life in mammalian cells. Protein Eng 12, 1035-1040. 
Cox,C.V., Evely,R.S., Oakhill,A., Pamphilon,D.H., Goulden,N.J., and Blair,A. 
(2004). Characterization of acute lymphoblastic leukemia progenitor cells. Blood 
104, 2919-2925. 
Dar,A., Goichberg,P., Shinder,V., Kalinkovich,A., Kollet,O., Netzer,N., 
Margalit,R., Zsak,M., Nagler,A., Hardan,I., Resnick,I., Rot,A., and Lapidot,T. 
(2005). Chemokine receptor CXCR4-dependent internalization and resecretion of 
functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat. 
Immunol. 6, 1038-1046. 
Das,A.V., James,J., Zhao,X., Rahnenfuhrer,J., and Ahmad,I. (2004). Identification 
of c-Kit receptor as a regulator of adult neural stem cells in the mammalian eye: 
interactions with Notch signaling. Dev. Biol. 273, 87-105. 
 87
de Bruijn,M.F., Ma,X., Robin,C., Ottersbach,K., Sanchez,M.J., and Dzierzak,E. 
(2002). Hematopoietic stem cells localize to the endothelial cell layer in the 
midgestation mouse aorta. Immunity. 16, 673-683. 
de Haan,G., Weersing,E., Dontje,B., van Os,R., Bystrykh,L.V., Vellenga,E., and 
Miller,G. (2003). In vitro generation of long-term repopulating hematopoietic stem 
cells by fibroblast growth factor-1. Dev. Cell 4, 241-251. 
Dexter,T.M., Spooncer,E., Schofield,R., Lord,B.I., and Simmons,P. (1984). 
Haemopoietic stem cells and the problem of self-renewal. Blood Cells 10, 315-339. 
Doi,H., Inaba,M., Yamamoto,Y., Taketani,S., Mori,S.I., Sugihara,A., Ogata,H., 
Toki,J., Hisha,H., Inaba,K., Sogo,S., Adachi,M., Matsuda,T., Good,R.A., and 
Ikehara,S. (1997). Pluripotent hemopoietic stem cells are c-kit<low. Proc. Natl. 
Acad. Sci. U. S. A 94, 2513-2517. 
Dolci,S., Williams,D.E., Ernst,M.K., Resnick,J.L., Brannan,C.I., Lock,L.F., 
Lyman,S.D., Boswell,H.S., and Donovan,P.J. (1991). Requirement for mast cell 
growth factor for primordial germ cell survival in culture. Nature 352, 809-811. 
Dzierzak,E. (2002). Hematopoietic stem cells and their precursors: developmental 
diversity and lineage relationships. Immunol. Rev. 187, 126-138. 
Dzierzak,E., Medvinsky,A., and de Bruijn,M. (1998). Qualitative and quantitative 
aspects of haematopoietic cell development in the mammalian embryo. Immunol. 
Today 19, 228-236. 
Eberhard,D. and Jockusch,H. (2005). Patterns of myocardial histogenesis as 
revealed by mouse chimeras. Dev. Biol. 278, 336-346. 
El Badri,N.S., Wang,B.Y., Cherry, and Good,R.A. (1998). Osteoblasts promote 
engraftment of allogeneic hematopoietic stem cells. Exp. Hematol. 26, 110-116. 
Ema,H. and Nakauchi,H. (2000). Expansion of hematopoietic stem cells in the 
developing liver of a mouse embryo. Blood 95, 2284-2288. 
Enver,T. and Greaves,M. (1998). Loops, lineage, and leukemia. Cell 94, 9-12. 
Fazel,S., Cimini,M., Chen,L., Li,S., Angoulvant,D., Fedak,P., Verma,S., 
Weisel,R.D., Keating,A., and Li,R.K. (2006). Cardioprotective c-kit+ cells are from 
the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. 
Clin. Invest 116, 1865-1877. 
Flanagan,J.G., Chan,D.C., and Leder,P. (1991). Transmembrane form of the kit 
ligand growth factor is determined by alternative splicing and is missing in the Sld 
mutant. Cell 64, 1025-1035. 
Flanagan,J.G. and Leder,P. (1990). The kit ligand: a cell surface molecule altered in 
steel mutant fibroblasts. Cell 63, 185-194. 
 88
Fleischman,R.A., Saltman,D.L., Stastny,V., and Zneimer,S. (1991). Deletion of the 
c-kit protooncogene in the human developmental defect piebald trait. Proc. Natl. 
Acad. Sci. U. S. A 88, 10885-10889. 
Fuchs,E., Tumbar,T., and Guasch,G. (2004). Socializing with the neighbors: stem 
cells and their niche. Cell 116, 769-778. 
Furitsu,T., Tsujimura,T., Tono,T., Ikeda,H., Kitayama,H., Koshimizu,U., 
Sugahara,H., Butterfield,J.H., Ashman,L.K., Kanayama,Y., and . (1993). 
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a 
human mast cell leukemia cell line causing ligand-independent activation of c-kit 
product. J. Clin. Invest 92, 1736-1744. 
Geissler,E.N., Ryan,M.A., and Housman,D.E. (1988). The dominant-white spotting 
(W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55, 185-192. 
Gokkel,E., Grossman,Z., Ramot,B., Yarden,Y., Rechavi,G., and Givol,D. (1992). 
Structural organization of the murine c-kit proto-oncogene. Oncogene 7, 1423-
1429. 
Golde,D.W. (1991). The stem cell. Science America 265, 86-93. 
Goldman,J.M. (1982). Blood and its disorders. London: Blackwell Scientific 
Publications. 
Goodell,M.A., Brose,K., Paradis,G., Conner,A.S., and Mulligan,R.C. (1996). 
Isolation and functional properties of murine hematopoietic stem cells that are 
replicating in vivo. J. Exp. Med. 183, 1797-1806. 
Griffin,J.D. and Lowenberg,B. (1986). Clonogenic cells in acute myeloblastic 
leukemia. Blood 68, 1185-1195. 
Gussoni,E., Soneoka,Y., Strickland,C.D., Buzney,E.A., Khan,M.K., Flint,A.F., 
Kunkel,L.M., and Mulligan,R.C. (1999). Dystrophin expression in the mdx mouse 
restored by stem cell transplantation. Nature 401, 390-394. 
Hamburger,A.W. and Salmon,S.E. (1977). Primary bioassay of human tumor stem 
cells. Science 197, 461-463. 
Hao,Q.L., Zhu,J., Price,M.A., Payne,K.J., Barsky,L.W., and Crooks,G.M. (2001). 
Identification of a novel, human multilymphoid progenitor in cord blood. Blood 97, 
3683-3690. 
Harrison,D.E., Astle,C.M., and Delaittre,J.A. (1978). Loss of proliferative capacity 
in immunohemopoietic stem cells caused by serial transplantation rather than aging. 
J. Exp. Med. 147, 1526-1531. 
Harrison,D.E., Astle,C.M., and Lerner,C. (1988). Number and continuous 
proliferative pattern of transplanted primitive immunohematopoietic stem cells. 
Proc. Natl. Acad. Sci. U. S. A 85, 822-826. 
 89
Harrison,D.E., Jordan,C.T., Zhong,R.K., and Astle,C.M. (1993). Primitive 
hemopoietic stem cells: direct assay of most productive populations by competitive 
repopulation with simple binomial, correlation and covariance calculations. Exp. 
Hematol. 21, 206-219. 
Harrison,D.E. and Zhong,R.K. (1992). The same exhaustible multilineage precursor 
produces both myeloid and lymphoid cells as early as 3-4 weeks after marrow 
transplantation. Proc. Natl. Acad. Sci. U. S. A 89, 10134-10138. 
Hayashi,S., Kunisada,T., Ogawa,M., Yamaguchi,K., and Nishikawa,S. (1991). 
Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. 
Nucleic Acids Res. 19, 1267-1271. 
Heissig,B., Hattori,K., Dias,S., Friedrich,M., Ferris,B., Hackett,N.R., Crystal,R.G., 
Besmer,P., Lyden,D., Moore,M.A., Werb,Z., and Rafii,S. (2002). Recruitment of 
stem and progenitor cells from the bone marrow niche requires MMP-9 mediated 
release of kit-ligand. Cell 109, 625-637. 
Hemmati,H.D., Nakano,I., Lazareff,J.A., Masterman-Smith,M., Geschwind,D.H., 
Bronner-Fraser,M., and Kornblum,H.I. (2003). Cancerous stem cells can arise from 
pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A 100, 15178-15183. 
Hierlihy,A.M., Seale,P., Lobe,C.G., Rudnicki,M.A., and Megeney,L.A. (2002). 
The post-natal heart contains a myocardial stem cell population. FEBS Lett. 530, 
239-243. 
Hirota,S., Isozaki,K., Moriyama,Y., Hashimoto,K., Nishida,T., Ishiguro,S., 
Kawano,K., Hanada,M., Kurata,A., Takeda,M., Muhammad,T.G., Matsuzawa,Y., 
Kanakura,Y., Shinomura,Y., and Kitamura,Y. (1998). Gain-of-function mutations 
of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580. 
Hristov,M. and Weber,C. (2004). Endothelial progenitor cells: characterization, 
pathophysiology, and possible clinical relevance. J. Cell Mol. Med. 8, 498-508. 
Hu,M., Krause,D., Greaves,M., Sharkis,S., Dexter,M., Heyworth,C., and Enver,T. 
(1997). Multilineage gene expression precedes commitment in the hemopoietic 
system. Genes Dev. 11, 774-785. 
Huang,E., Nocka,K., Beier,D.R., Chu,T.Y., Buck,J., Lahm,H.W., Wellner,D., 
Leder,P., and Besmer,P. (1990). The hematopoietic growth factor KL is encoded by 
the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. 
Cell 63, 225-233. 
Huizinga,J.D., Thuneberg,L., Kluppel,M., Malysz,J., Mikkelsen,H.B., and 
Bernstein,A. (1995). W/kit gene required for interstitial cells of Cajal and for 
intestinal pacemaker activity. Nature 373, 347-349. 
 
Hume,D.A. (2000). Probability in transcriptional regulation and its implications for 
leukocyte differentiation and inducible gene expression. Blood 96, 2323-2328. 
 
 90
Ianus,A., Holz,G.G., Theise,N.D., and Hussain,M.A. (2003). In vivo derivation of 
glucose-competent pancreatic endocrine cells from bone marrow without evidence 
of cell fusion. J. Clin. Invest 111, 843-850. 
Ignatova,T.N., Kukekov,V.G., Laywell,E.D., Suslov,O.N., Vrionis,F.D., and 
Steindler,D.A. (2002). Human cortical glial tumors contain neural stem-like cells 
expressing astroglial and neuronal markers in vitro. Glia 39, 193-206. 
Ikuta,K. and Weissman,I.L. (1992). Evidence that hematopoietic stem cells 
express mouse c-kit but do not depend on steel factor for their generation. Proc. 
Natl. Acad. Sci. U. S. A 89, 1502-1506. 
Jackson,K.A., Majka,S.M., Wang,H., Pocius,J., Hartley,C.J., Majesky,M.W., 
Entman,M.L., Michael,L.H., Hirschi,K.K., and Goodell,M.A. (2001). Regeneration 
of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. 
Invest 107, 1395-1402. 
Jaffredo,T., Gautier,R., Eichmann,A., and Dieterlen-Lievre,F. (1998). Intraaortic 
hemopoietic cells are derived from endothelial cells during ontogeny. Development 
125, 4575-4583. 
Jamieson,C.H., Ailles,L.E., Dylla,S.J., Muijtjens,M., Jones,C., Zehnder,J.L., 
Gotlib,J., Li,K., Manz,M.G., Keating,A., Sawyers,C.L., and Weissman,I.L. (2004). 
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-
crisis CML. N. Engl. J. Med. 351, 657-667. 
Jones,D.L. and Fuller,M.T. (2004). Stem cell niche. In Handbook of stem cells, 
R.Lanza, ed. (Boston, Massachusetts, USA: Elsevier Academic), pp. 59-71. 
Jordan,C.T., Upchurch,D., Szilvassy,S.J., Guzman,M.L., Howard,D.S., 
Pettigrew,A.L., Meyerrose,T., Rossi,R., Grimes,B., Rizzieri,D.A., Luger,S.M., and 
Phillips,G.L. (2000). The interleukin-3 receptor alpha chain is a unique marker for 
human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784. 
Kaneko,Y., Sakakibara,S., Imai,T., Suzuki,A., Nakamura,Y., Sawamoto,K., 
Ogawa,Y., Toyama,Y., Miyata,T., and Okano,H. (2000). Musashi1: an 
evolutionally conserved marker for CNS progenitor cells including neural stem 
cells. Dev. Neurosci. 22, 139-153. 
Katayama,N., Shih,J.P., Nishikawa,S., Kina,T., Clark,S.C., and Ogawa,M. (1993). 
Stage-specific expression of c-kit protein by murine hematopoietic progenitors. 
Blood 82, 2353-2360. 
 
Katayama,Y., Battista,M., Kao,W.M., Hidalgo,A., Peired,A.J., Thomas,S.A., 
and Frenette,P.S. (2006). Signals from the sympathetic nervous system regulate 
hematopoietic stem cell egress from bone marrow. Cell 124, 407-421.
 
Katayama,Y., Hidalgo,A., Furie,B.C., Vestweber,D., Furie,B., and Frenette,P.S. 
(2003). PSGL-1 participates in E-selectin-mediated progenitor homing to bone 
marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. 
Blood 102, 2060-2067.   
 91
Kattman,S.J., Huber,T.L., and Keller,G.M. (2006). Multipotent flk-1+ 
cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and 
vascular smooth muscle lineages. Dev. Cell 11, 723-732. 
Kawada,H., Fujita,J., Kinjo,K., Matsuzaki,Y., Tsuma,M., Miyatake,H., 
Muguruma,Y., Tsuboi,K., Itabashi,Y., Ikeda,Y., Ogawa,S., Okano,H., Hotta,T., 
Ando,K., and Fukuda,K. (2004). Nonhematopoietic mesenchymal stem cells can be 
mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 
104, 3581-3587. 
Keyoung,H.M., Roy,N.S., Benraiss,A., Louissaint,A., Jr., Suzuki,A., 
Hashimoto,M., Rashbaum,W.K., Okano,H., and Goldman,S.A. (2001). High-yield 
selection and extraction of two promoter-defined phenotypes of neural stem cells 
from the fetal human brain. Nat. Biotechnol. 19, 843-850. 
Kiel,M.J., Yilmaz,O.H., Iwashita,T., Yilmaz,O.H., Terhorst,C., and Morrison,S.J. 
(2005). SLAM family receptors distinguish hematopoietic stem and progenitor cells 
and reveal endothelial niches for stem cells. Cell 121, 1109-1121. 
Kim,H.J., Tisdale,J.F., Wu,T., Takatoku,M., Sellers,S.E., Zickler,P., Metzger,M.E., 
Agricola,B.A., Malley,J.D., Kato,I., Donahue,R.E., Brown,K.E., and Dunbar,C.E. 
(2000). Many multipotential gene-marked progenitor or stem cell clones contribute 
to hematopoiesis in nonhuman primates. Blood 96, 1-8. 
Kim,I., He,S., Yilmaz,O.H., Kiel,M.J., and Morrison,S.J. (2006). Enhanced 
purification of fetal liver hematopoietic stem cells using SLAM family receptors. 
Blood 108, 737-744. 
Klarmann,K., Ortiz,M., Davies,M., and Keller,J.R. (2003). Identification of in vitro 
growth conditions for c-Kit-negative hematopoietic stem cells. Blood 102, 3120-
3128. 
Kobayashi-Osaki,M., Ohneda,O., Suzuki,N., Minegishi,N., Yokomizo,T., 
Takahashi,S., Lim,K.C., Engel,J.D., and Yamamoto,M. (2005). GATA motifs 
regulate early hematopoietic lineage-specific expression of the Gata2 gene. Mol. 
Cell Biol. 25, 7005-7020. 
Kondo,M., Weissman,I.L., and Akashi,K. (1997). Identification of clonogenic 
common lymphoid progenitors in mouse bone marrow. Cell 91, 661-672. 
 
Kopp,H.G., Avecilla,S.T., Hooper,A.T., and Rafii,S. (2005). The bone marrow vascular 
niche: home of HSC differentiation and mobilization. Physiology. (Bethesda. ) 20, 
349-356. 
 
Kortesidis,A., Zannettino,A., Isenmann,S., Shi,S., Lapidot,T., and Gronthos,S. (2005). 
Stromal-derived factor-1 promotes the growth, survival, and development of human
bone marrow stromal stem cells. Blood 105, 3793-3801.
 
Kotton,D.N., Fabian,A.J., and Mulligan,R.C. (2005). A novel stem-cell population in 
adult liver with potent hematopoietic-reconstitution activity. Blood 106, 1574-1580.   
 92
Kubo,H. and Alitalo,K. (2003). The bloody fate of endothelial stem cells. Genes 
Dev. 17, 322-329. 
Kumaravelu,P., Hook,L., Morrison,A.M., Ure,J., Zhao,S., Zuyev,S., Ansell,J., and 
Medvinsky,A. (2002). Quantitative developmental anatomy of definitive 
haematopoietic stem cells/long-term repopulating units (HSC/RUs): role of the 
aorta-gonad-mesonephros (AGM) region and the yolk sac in colonisation of the 
mouse embryonic liver. Development 129, 4891-4899. 
Lacaud,G., Robertson,S., Palis,J., Kennedy,M., and Keller,G. (2001). Regulation of 
hemangioblast development. Ann. N. Y. Acad. Sci. 938, 96-107. 
Lapidot,T., Dar,A., and Kollet,O. (2005). How do stem cells find their way home? 
Blood 106, 1901-1910. 
Lapidot,T., Sirard,C., Vormoor,J., Murdoch,B., Hoang,T., Caceres-Cortes,J., 
Minden,M., Paterson,B., Caligiuri,M.A., and Dick,J.E. (1994). A cell initiating 
human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 
645-648. 
Laugwitz,K.L., Moretti,A., Lam,J., Gruber,P., Chen,Y., Woodard,S., Lin,L.Z., 
Cai,C.L., Lu,M.M., Reth,M., Platoshyn,O., Yuan,J.X., Evans,S., and Chien,K.R. 
(2005a). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte 
lineages. Nature 433, 647-653. 
Lee,T.I., Jenner,R.G., Boyer,L.A., Guenther,M.G., Levine,S.S., Kumar,R.M., 
Chevalier,B., Johnstone,S.E., Cole,M.F., Isono,K., Koseki,H., Fuchikami,T., 
Abe,K., Murray,H.L., Zucker,J.P., Yuan,B., Bell,G.W., Herbolsheimer,E., 
Hannett,N.M., Sun,K., Odom,D.T., Otte,A.P., Volkert,T.L., Bartel,D.P., 
Melton,D.A., Gifford,D.K., Jaenisch,R., and Young,R.A. (2006). Control of 
developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 
301-313. 
Lemieux,M.E. and Eaves,C.J. (1996). Identification of properties that can 
distinguish primitive populations of stromal-cell-responsive lympho-myeloid cells
from cells that are stromal-cell-responsive but lymphoid-restricted and cells that have 
lympho-myeloid potential but are also capable of competitively repopulating 
myeloablated recipients. Blood 88, 1639-1648. 
 
Li,L. (2005). Finding the hematopoietic stem cell niche in the placenta. Dev.
Cell 8, 297-298.
 
Li,L., Milner,L.A., Deng,Y., Iwata,M., Banta,A., Graf,L., Marcovina,S., Friedman,C., 
Trask,B.J., Hood,L., and Torok-Storb,B. (1998). The human homolog of rat Jagged1 
expressed by marrow stroma inhibits differentiation of 32D cells through interaction 
with Notch1. Immunity. 8, 43-55. 
 
Li,L. and Xie,T. (2005). Stem cell niche: structure and function. Annu. Rev. Cell Dev. 
Biol. 21, 605-631.   
 
 93
Li,W., Johnson,S.A., Shelley,W.C., and Yoder,M.C. (2004). Hematopoietic stem 
cell repopulating ability can be maintained in vitro by some primary endothelial 
cells. Exp. Hematol. 32, 1226-1237. 
Ling,K.W., Ottersbach,K., van Hamburg,J.P., Oziemlak,A., Tsai,F.Y., Orkin,S.H., 
Ploemacher,R., Hendriks,R.W., and Dzierzak,E. (2004). GATA-2 plays two 
functionally distinct roles during the ontogeny of hematopoietic stem cells. J. Exp. 
Med. 200, 871-882. 
Longley,B.J., Jr., Metcalfe,D.D., Tharp,M., Wang,X., Tyrrell,L., Lu,S.Z., 
Heitjan,D., and Ma,Y. (1999). Activating and dominant inactivating c-KIT catalytic 
domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. 
Acad. Sci. U. S. A 96, 1609-1614. 
Ma,X., Robin,C., Ottersbach,K., and Dzierzak,E. (2002). The Ly-6A (Sca-1) GFP 
transgene is expressed in all adult mouse hematopoietic stem cells. Stem Cells 20, 
514-521. 
Magli,M.C., Iscove,N.N., and Odartchenko,N. (1982). Transient nature of early 
haematopoietic spleen colonies. Nature 295, 527-529. 
Manz,M.G., Miyamoto,T., Akashi,K., and Weissman,I.L. (2002). Prospective 
isolation of human clonogenic common myeloid progenitors. Proc. Natl. Acad. Sci. 
U. S. A 99, 11872-11877. 
Martin,C.M., Meeson,A.P., Robertson,S.M., Hawke,T.J., Richardson,J.A., Bates,S., 
Goetsch,S.C., Gallardo,T.D., and Garry,D.J. (2004). Persistent expression of the 
ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the 
developing and adult heart. Dev. Biol. 265, 262-275. 
Matsuura,K., Nagai,T., Nishigaki,N., Oyama,T., Nishi,J., Wada,H., Sano,M., 
Toko,H., Akazawa,H., Sato,T., Nakaya,H., Kasanuki,H., and Komuro,I. (2004).
Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. 
J. Biol. Chem. 279, 11384-11391. 
 
Matsuzaki,Y., Kinjo,K., Mulligan,R.C., and Okano,H. (2004). Unexpectedly 
efficient homing capacity of purified murine hematopoietic stem cells. 
Immunity. 20, 87-93.
 
McQuibban,G.A., Butler,G.S., Gong,J.H., Bendall,L., Power,C., Clark-Lewis,I., 
and Overall,C.M. (2001). Matrix metalloproteinase activity inactivates the CXC 
chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503-43508. 
 
Mendes,S.C., Robin,C., and Dzierzak,E. (2005). Mesenchymal progenitor cells 
localize within hematopoietic sites throughout ontogeny. Development 132, 1127-1136. 
 
Messina,E., De Angelis,L., Frati,G., Morrone,S., Chimenti,S., Fiordaliso,F., Salio,M., 
Battaglia,M., Latronico,M.V., Coletta,M., Vivarelli,E., Frati,L., Cossu,G., and Giacomello,A. 
(2004). Isolation and expansion of adult cardiac stem cells from human and murine heart. 
Circ. Res. 95, 911-921.   
 94
Metcalf,D. (1999). Cellular hematopoiesis in the twentieth century. Semin. Hematol. 
36, 5-12. 
 
Minasi,M.G., Riminucci,M., De Angelis,L., Borello,U., Berarducci,B., Innocenzi,A., 
Caprioli,A., Sirabella,D., Baiocchi,M., De Maria,R., Boratto,R., Jaffredo,T., Broccoli,V., 
Bianco,P., and Cossu,G. (2002). The meso-angioblast: a multipotent, self-renewing
 cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. 
Development 129, 2773-2783.
 
Minegishi,N., Ohta,J., Yamagiwa,H., Suzuki,N., Kawauchi,S., Zhou,Y., Takahashi,S., 
Hayashi,N., Engel,J.D., and Yamamoto,M. (1999). The mouse GATA-2 gene is 
expressed in the para-aortic splanchnopleura and aorta-gonads and mesonephros 
region. Blood 93, 4196-4207. 
 
Mintz,B. and Russell,E.S. (1957). Gene-induced embryological modifications of 
primordial germ cells in the mouse. J. Exp. Zool. 134, 207-237. 
 
Molofsky,A.V., Pardal,R., Iwashita,T., Park,I.K., Clarke,M.F., and Morrison,S.J. 
(2003). Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor
proliferation. Nature 425, 962-967. 
 
Moore,K.A. and Lemischka,I.R. (2006). Stem cells and their niches. Science 311, 
1880-1885. 
 
Moretti,A., Caron,L., Nakano,A., Lam,J.T., Bernshausen,A., Chen,Y., Qyang,Y., 
Bu,L., Sasaki,M., Martin-Puig,S., Sun,Y., Evans,S.M., Laugwitz,K.L., and 
Chien,K.R. (2006). Multipotent embryonic isl1+ progenitor cells lead to cardiac, 
smooth muscle, and endothelial cell diversification. Cell 127, 1151-1165.
 
Morita,Y., Ema,H., Yamazaki,S., and Nakauchi,H. (2006). Non-side-population 
hematopoietic stem cells in mouse bone marrow. Blood 108, 2850-2856. 
 
Moriyama,Y., Tsujimura,T., Hashimoto,K., Morimoto,M., Kitayama,H., Matsuzawa, 
Kitamura,Y., and Kanakura,Y. (1996). Role of aspartic acid 814 in the function and 
expression of c-kit receptor tyrosine kinase. J. Biol. Chem. 271, 3347-3350. 
 
Morrison,S.J., Hemmati,H.D., Wandycz,A.M., and Weissman,I.L. (1995). The 
purification and characterization of fetal liver hematopoietic stem cells. 
Proc. Natl. Acad. Sci. U. S. A 92, 10302-10306.   
 
Morrison,S.J. and Weissman,I.L. (1994). The long-term repopulating subset of 
hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1, 661-673. 
 
Mouquet,F., Pfister,O., Jain,M., Oikonomopoulos,A., Ngoy,S., Summer,R., Fine,A., 
and Liao,R. (2005). Restoration of cardiac progenitor cells after myocardial infarction 
by self-proliferation and selective homing of bone marrow-derived stem cells. 
Circ. Res. 97, 1090-1092. 
 
Muguruma,Y., Yahata,T., Miyatake,H., Sato,T., Uno,T., Itoh,J., Kato,S., Ito,M., Hotta,T., 
and Ando,K. (2006). Reconstitution of the functional human hematopoietic microenvironment 
derived from human mesenchymal stem cells in the murine bone marrow compartment. 
Blood 107, 1878-1887.  
 95
Munugalavadla,V., Dore,L.C., Tan,B.L., Hong,L., Vishnu,M., Weiss,M.J., and 
Kapur,R. (2005). Repression of c-kit and its downstream substrates by GATA-1 
inhibits cell proliferation during erythroid maturation. Mol. Cell Biol. 25, 6747-
6759. 
 
Nakahara,M., Isozaki,K., Hirota,S., Miyagawa,J., Hase-Sawada,N., Taniguchi,M., 
Nishida,T., Kanayama,S., Kitamura,Y., Shinomura,Y., and Matsuzawa,Y. (1998). A 
novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. 
Gastroenterology 115, 1090-1095. 
 
Nakauchi,H. (1998). Hematopoietic stem cells: are they CD34-positive or CD34-negative? 
Nat. Med. 4, 1009-1010. 
 
Nilsson,S.K., Johnston,H.M., Whitty,G.A., Williams,B., Webb,R.J., Denhardt,D.T., 
Bertoncello,I., Bendall,L.J., Simmons,P.J., and Haylock,D.N. (2005). Osteopontin, 
a key component of the hematopoietic stem cell niche and regulator of primitive 
hematopoietic progenitor cells. Blood 106, 1232-1239.
 
Nishida,T., Hirota,S., Taniguchi,M., Hashimoto,K., Isozaki,K., Nakamura,H., Kanakura,Y., 
Tanaka,T., Takabayashi,A., Matsuda,H., and Kitamura,Y. (1998). Familial gastrointestinal 
stromal tumours with germline mutation of the KIT gene. Nat. Genet. 19, 323-324. 
 
Nishikawa,S.I. (2001). A complex linkage in the developmental pathway of endothelial 
and hematopoietic cells. Curr. Opin. Cell Biol. 13, 673-678. 
 
Nocka,K., Buck,J., Levi,E., and Besmer,P. (1990). Candidate ligand for the c-kit 
transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells 
and erythroid progenitors. EMBO J. 9, 3287-3294. 
 
North,T.E., de Bruijn,M.F., Stacy,T., Talebian,L., Lind,E., Robin,C., Binder,M., Dzierzak,E., 
and Speck,N.A. (2002). Runx1 expression marks long-term repopulating hematopoietic 
stem cells in the midgestation mouse embryo. Immunity. 16, 661-672.
 
Nygren,J.M., Bryder,D., and Jacobsen,S.E. (2006). Prolonged cell cycle transit is a defining 
and developmentally conserved hemopoietic stem cell property. J. Immunol. 177, 201-208.
 
O'Brien,C.A., Pollett,A., Gallinger,S., and Dick,J.E. (2007). A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110. 
 
Oberlin,E., Tavian,M., Blazsek,I., and Peault,B. (2002). Blood-forming potential of vascular 
endothelium in the human embryo. Development 129, 4147-4157. 
 
Ogawa,M. (1993). Differentiation and proliferation of hematopoietic stem cells. 
Blood 81, 2844-2853.
 
Ogawa,M. (1999). Stochastic model revisited. Int. J. Hematol. 69, 2-5. 
 
Ogawa,M., Matsuzaki,Y., Nishikawa,S., Hayashi,S., Kunisada,T., Sudo,T., Kina,T., 
Nakauchi,H., and Nishikawa,S. (1991). Expression and function of c-kit in hemopoietic 
progenitor cells. J. Exp. Med. 174, 63-71.    
 96
Oh,H., Bradfute,S.B., Gallardo,T.D., Nakamura,T., Gaussin,V., Mishina,Y., 
Pocius,J., Michael,L.H., Behringer,R.R., Garry,D.J., Entman,M.L., and 
Schneider,M.D. (2003a). Cardiac progenitor cells from adult myocardium: homing, 
differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. U. S. A 100, 
12313-12318. 
Okada,S., Nagayoshi,K., Nakauchi,H., Nishikawa,S., Miura,Y., and Suda,T. 
(1993). Sequential analysis of hematopoietic reconstitution achieved by 
transplantation of hematopoietic stem cells. Blood 81, 1720-1725. 
Okuno,Y., Huettner,C.S., Radomska,H.S., Petkova,V., Iwasaki,H., Akashi,K., and 
Tenen,D.G. (2002). Distal elements are critical for human CD34 expression in vivo. 
Blood 100, 4420-4426. 
Orlic,D., Kajstura,J., Chimenti,S., Jakoniuk,I., Anderson,S.M., Li,B., Pickel,J., 
McKay,R., Nadal-Ginard,B., Bodine,D.M., Leri,A., and Anversa,P. (2001). Bone 
marrow cells regenerate infarcted myocardium. Nature 410, 701-705. 
Oshima,H., Rochat,A., Kedzia,C., Kobayashi,K., and Barrandon,Y. (2001). 
Morphogenesis and renewal of hair follicles from adult multipotent stem cells. Cell 
104, 233-245. 
Overturf,K., Al Dhalimy,M., Ou,C.N., Finegold,M., and Grompe,M. (1997). Serial 
transplantation reveals the stem-cell-like regenerative potential of adult mouse 
hepatocytes. Am. J. Pathol. 151, 1273-1280. 
Palis,J. and Yoder,M.C. (2001). Yolk-sac hematopoiesis: the first blood cells of 
mouse and man. Exp. Hematol. 29, 927-936. 
Papayannopoulou,T. (2004). Current mechanistic scenarios in hematopoietic 
stem/progenitor cell mobilization. Blood 103, 1580-1585. 
Park,C.H., Bergsagel,D.E., and McCulloch,E.A. (1971). Mouse myeloma tumor 
stem cells: a primary cell culture assay. J. Natl. Cancer Inst. 46, 411-422. 
Park,I.K., Qian,D., Kiel,M., Becker,M.W., Pihalja,M., Weissman,I.L., 
Morrison,S.J., and Clarke,M.F. (2003). Bmi-1 is required for maintenance of adult 
self-renewing haematopoietic stem cells. Nature 423, 302-305. 
Parmacek,M.S. and Epstein,J.A. (2005). Pursuing cardiac progenitors: regeneration 
redux. Cell 120, 295-298. 
Passegue,E., Wagers,A.J., Giuriato,S., Anderson,W.C., and Weissman,I.L. (2005). 
Global analysis of proliferation and cell cycle gene expression in the regulation of 
hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599-1611. 
Peled,A., Grabovsky,V., Habler,L., Sandbank,J., Arenzana-Seisdedos,F., Petit,I., 
Ben Hur,H., Lapidot,T., and Alon,R. (1999). The chemokine SDF-1 stimulates
integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. 
J. Clin. Invest 104, 1199-1211.  
 97
Petit,I., Szyper-Kravitz,M., Nagler,A., Lahav,M., Peled,A., Habler,L., 
Ponomaryov,T., Taichman,R.S., Arenzana-Seisdedos,F., Fujii,N., Sandbank,J., 
Zipori,D., and Lapidot,T. (2002). G-CSF induces stem cell mobilization by 
decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3, 687-
694. 
Pfister,O., Mouquet,F., Jain,M., Summer,R., Helmes,M., Fine,A., Colucci,W.S., 
and Liao,R. (2005). CD31- but Not CD31+ cardiac side population cells exhibit 
functional cardiomyogenic differentiation. Circ. Res. 97, 52-61. 
Potocnik,A.J., Brakebusch,C., and Fassler,R. (2000). Fetal and adult hematopoietic 
stem cells require beta1 integrin function for colonizing fetal liver, spleen, and bone 
marrow. Immunity. 12, 653-663. 
Quaini,F., Urbanek,K., Beltrami,A.P., Finato,N., Beltrami,C.A., Nadal-Ginard,B., 
Kajstura,J., Leri,A., and Anversa,P. (2002). Chimerism of the transplanted heart. N. 
Engl. J. Med. 346, 5-15. 
Reya,T., Duncan,A.W., Ailles,L., Domen,J., Scherer,D.C., Willert,K., Hintz,L., 
Nusse,R., and Weissman,I.L. (2003). A role for Wnt signalling in self-renewal of 
haematopoietic stem cells. Nature 423, 409-414. 
Reynolds,B.A. and Weiss,S. (1992). Generation of neurons and astrocytes from 
isolated cells of the adult mammalian central nervous system. Science 255, 1707-
1710. 
Ricci-Vitiani,L., Lombardi,D.G., Pilozzi,E., Biffoni,M., Todaro,M., Peschle,C., and 
De Maria,R. (2007). Identification and expansion of human colon-cancer-initiating 
cells. Nature 445, 111-115. 
Rubin,B.P., Antonescu,C.R., Scott-Browne,J.P., Comstock,M.L., Gu,Y., 
Tanas,M.R., Ware,C.B., and Woodell,J. (2005). A knock-in mouse model of 
gastrointestinal stromal tumor harboring kit K641E. Cancer Res. 65, 6631-6639. 
Sabbath,K.D., Ball,E.D., Larcom,P., Davis,R.B., and Griffin,J.D. (1985). 
Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J. Clin. Invest 
75, 746-753. 
Sakakibara,S., Imai,T., Hamaguchi,K., Okabe,M., Aruga,J., Nakajima,K., 
Yasutomi,D., Nagata,T., Kurihara,Y., Uesugi,S., Miyata,T., Ogawa,M., 
Mikoshiba,K., and Okano,H. (1996). Mouse-Musashi-1, a neural RNA-binding 
protein highly enriched in the mammalian CNS stem cell. Dev. Biol. 176, 230-242. 
Sanchez,M.J., Bockamp,E.O., Miller,J., Gambardella,L., and Green,A.R. (2001). 
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing 
Scl under the control of a stem cell enhancer. Development 128, 4815-4827. 
 98
Sanchez,M.J., Holmes,A., Miles,C., and Dzierzak,E. (1996). Characterization of the 
first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. 
Immunity. 5, 513-525. 
Sato,T., Laver,J.H., and Ogawa,M. (1999). Reversible expression of CD34 by 
murine hematopoietic stem cells. Blood 94, 2548-2554. 
Semerad,C.L., Christopher,M.J., Liu,F., Short,B., Simmons,P.J., Winkler,I., 
Levesque,J.P., Chappel,J., Ross,F.P., and Link,D.C. (2005). G-CSF potently 
inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. 
Blood 106, 3020-3027. 
Silberstein,L., Sanchez,M.J., Socolovsky,M., Liu,Y., Hoffman,G., Kinston,S., 
Piltz,S., Bowen,M., Gambardella,L., Green,A.R., and Gottgens,B. (2005). 
Transgenic analysis of the stem cell leukemia +19 stem cell enhancer in adult and 
embryonic hematopoietic and endothelial cells. Stem Cells 23, 1378-1388. 
Siminovitch,L., McCulloch,E.A., and Till,J.E. (1963). The distribution of 
colony-forming cells among spleen colonies. J. Cell Physiol 62, 327-336. 
Singh,S.K., Clarke,I.D., Terasaki,M., Bonn,V.E., Hawkins,C., Squire,J., and 
Dirks,P.B. (2003). Identification of a cancer stem cell in human brain tumors. 
Cancer Res. 63, 5821-5828. 
Singh,S.K., Hawkins,C., Clarke,I.D., Squire,J.A., Bayani,J., Hide,T., 
Henkelman,R.M., Cusimano,M.D., and Dirks,P.B. (2004). Identification of human 
brain tumour initiating cells. Nature 432, 396-401. 
Smith, R. R., Barile, L., Cho, H. C., Leppo, M. K., Hare, J. M., Messina, E., 
Giacomello, A., Abraham, M. R., and Marban, E. Regenerative potential of 
cardiosphere-derived cells expanded from percutaneous endomyocardial biopsies. 
Circulation . (2007). 115, 896-908.
Song,X. and Xie,T. (2002). DE-cadherin-mediated cell adhesion is essential for 
maintaining somatic stem cells in the Drosophila ovary. Proc. Natl. Acad. Sci. U. S. 
A 99, 14813-14818. 
Spangrude,G.J. and Cooper,D.D. (2000). Paradigm shifts in stem-cell biology. 
Semin. Hematol. 37, 3-10. 
Spangrude,G.J. and Scollay,R. (1990). A simplified method for enrichment of 
mouse hematopoietic stem cells. Exp. Hematol. 18, 920-926. 
Staal,F.J. and Clevers,H.C. (2005). WNT signalling and haematopoiesis: a WNT-
WNT situation. Nat. Rev. Immunol. 5, 21-30. 
Steidl,U., Kronenwett,R., Rohr,U.P., Fenk,R., Kliszewski,S., Maercker,C., 
Neubert,P., Aivado,M., Koch,J., Modlich,O., Bojar,H., Gattermann,N., and Haas,R. 
(2002). Gene expression profiling identifies significant differences between the 
molecular phenotypes of bone marrow-derived and circulating human CD34+ 
hematopoietic stem cells. Blood 99, 2037-2044. 
 99
Stier,S., Ko,Y., Forkert,R., Lutz,C., Neuhaus,T., Grunewald,E., Cheng,T., 
Dombkowski,D., Calvi,L.M., Rittling,S.R., and Scadden,D.T. (2005). Osteopontin 
is a hematopoietic stem cell niche component that negatively regulates stem cell 
pool size. J. Exp. Med. 201, 1781-1791. 
Stull,L.B., Leppo,M.K., Szweda,L., Gao,W.D., and Marban,E. (2004). Chronic 
treatment with allopurinol boosts survival and cardiac contractility in murine 
postischemic cardiomyopathy. Circ. Res. 95, 1005-1011. 
Suda,T., Suda,J., and Ogawa,M. (1983). Single-cell origin of mouse hemopoietic 
colonies expressing multiple lineages in variable combinations. Proc. Natl. Acad. 
Sci. U. S. A 80, 6689-6693. 
Suda,T., Suda,J., and Ogawa,M. (1984). Disparate differentiation in mouse 
hemopoietic colonies derived from paired progenitors. Proc. Natl. Acad. Sci. U. S. 
A 81, 2520-2524. 
Sugiyama,D., Ogawa,M., Hirose,I., Jaffredo,T., Arai,K., and Tsuji,K. (2003). 
Erythropoiesis from acetyl LDL incorporating endothelial cells at the preliver stage. 
Blood 101, 4733-4738. 
Szilvassy,S.J., Ragland,P.L., Miller,C.L., and Eaves,C.J. (2003). The marrow 
homing efficiency of murine hematopoietic stem cells remains constant during 
ontogeny. Exp. Hematol. 31, 331-338. 
Taichman,R.S. and Emerson,S.G. (1998). The role of osteoblasts in the 
hematopoietic microenvironment. Stem Cells 16, 7-15. 
Tajima,F., Deguchi,T., Laver,J.H., Zeng,H., and Ogawa,M. (2001). Reciprocal 
expression of CD38 and CD34 by adult murine hematopoietic stem cells. Blood 97, 
2618-2624. 
Taoudi,S., Morrison,A.M., Inoue,H., Gribi,R., Ure,J., and Medvinsky,A. (2005). 
Progressive divergence of definitive haematopoietic stem cells from the endothelial 
compartment does not depend on contact with the foetal liver. Development 132, 
4179-4191. 
Tenen,D.G., Hromas,R., Licht,J.D., and Zhang,D.E. (1997). Transcription factors, 
normal myeloid development, and leukemia. Blood 90, 489-519. 
Thisse,B. and Thisse,C. (2005). Functions and regulations of fibroblast growth 
factor signaling during embryonic development. Dev. Biol. 287, 390-402. 
Till,J.E. and McCulloch,E.A. (1961). A direct measurement of the radiation 
sensitivity of normal mouse bone marrow cells. Radiat. Res. 14, 213-222. 
Torok-Storb,B., Iwata,M., Graf,L., Gianotti,J., Horton,H., and Byrne,M.C. (1999). 
Dissecting the marrow microenvironment. Ann. N. Y. Acad. Sci. 872, 164-170. 
Trentin,J.J. (1971). Determination of bone marrow stem cell differentiation by 
stromal hemopoietic inductive microenvironments (HIM). Am. J. Pathol. 65, 621-
628. 
 100
Uchida,N. and Weissman,I.L. (1992). Searching for hematopoietic stem cells: 
evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells in C57BL/Ka-
Thy-1.1 bone marrow. J. Exp. Med. 175, 175-184. 
Ullrich,A. and Schlessinger,J. (1990). Signal transduction by receptors with 
tyrosine kinase activity. Cell 61, 203-212. 
Van Zant,G. and Goldwasser,E. (1979). Competition between erythropoietin and 
colony-stimulating factor for target cells in mouse marrow. Blood 53, 946-965. 
Varnum-Finney,B., Xu,L., Brashem-Stein,C., Nourigat,C., Flowers,D., Bakkour,S., 
Pear,W.S., and Bernstein,I.D. (2000). Pluripotent, cytokine-dependent, 
hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat. 
Med. 6, 1278-1281. 
Visnjic,D., Kalajzic,Z., Rowe,D.W., Katavic,V., Lorenzo,J., and Aguila,H.L. 
(2004). Hematopoiesis is severely altered in mice with an induced osteoblast 
deficiency. Blood 103, 3258-3264. 
Wagers,A.J. (2005). Stem cell grand SLAM. Cell 121, 967-970. 
Wallenfang,M.R. and Matunis,E. (2003). Developmental biology. Orienting stem 
cells. Science 301, 1490-1491. 
Wang,Y., Haider,H.K., Ahmad,N., Zhang,D., and Ashraf,M. (2006). Evidence for 
ischemia induced host-derived bone marrow cell mobilization into cardiac 
allografts. J. Mol. Cell Cardiol. 41, 478-487. 
Watt,F.M. and Hogan,B.L. (2000). Out of Eden: stem cells and their niches. 
Science 287, 1427-1430. 
Williams,D.E., Eisenman,J., Baird,A., Rauch,C., Van Ness,K., March,C.J., 
Park,L.S., Martin,U., Mochizuki,D.Y., Boswell,H.S., and . (1990). Identification of 
a ligand for the c-kit proto-oncogene. Cell 63, 167-174. 
Wojakowski,W., Tendera,M., Michalowska,A., Majka,M., Kucia,M., 
Maslankiewicz,K., Wyderka,R., Ochala,A., and Ratajczak,M.Z. (2004). 
Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and 
mononuclear cells expressing early cardiac, muscle, and endothelial markers into 
peripheral blood in patients with acute myocardial infarction. Circulation 110, 
3213-3220. 
Wright,D.E., Wagers,A.J., Gulati,A.P., Johnson,F.L., and Weissman,I.L. (2001). 
Physiological migration of hematopoietic stem and progenitor cells. Science 294, 
1933-1936. 
Wright,N.A. (2000). Epithelial stem cell repertoire in the gut: clues to the origin of 
cell lineages, proliferative units and cancer. Int. J. Exp. Pathol. 81, 117-143. 
 101
Wu,S.M., Fujiwara,Y., Cibulsky,S.M., Clapham,D.E., Lien,C.L., Schultheiss,T.M., 
and Orkin,S.H. (2006). Developmental origin of a bipotential myocardial and 
smooth muscle cell precursor in the mammalian heart. Cell 127, 1137-1150. 
Wylie,C. (1999). Germ cells. Cell 96, 165-174. 
Yamamoto,K., Tojo,A., Aoki,N., and Shibuya,M. (1993). Characterization of the 
promoter region of the human c-kit proto-oncogene. Jpn. J. Cancer Res. 84, 1136-
1144. 
Yamashita,Y.M., Jones,D.L., and Fuller,M.T. (2003). Orientation of asymmetric 
stem cell division by the APC tumor suppressor and centrosome. Science 301, 
1547-1550. 
Yang,F.C., Atkinson,S.J., Gu,Y., Borneo,J.B., Roberts,A.W., Zheng,Y., 
Pennington,J., and Williams,D.A. (2001). Rac and Cdc42 GTPases control 
hematopoietic stem cell shape, adhesion, migration, and mobilization. Proc. Natl. 
Acad. Sci. U. S. A 98, 5614-5618. 
Yasuda,H., Galli,S.J., and Geissler,E.N. (1993). Cloning and functional analysis of 
the mouse c-kit promoter. Biochem. Biophys. Res. Commun. 191, 893-901. 
Zhang,J., Niu,C., Ye,L., Huang,H., He,X., Tong,W.G., Ross,J., Haug,J., 
Johnson,T., Feng,J.Q., Harris,S., Wiedemann,L.M., Mishina,Y., and Li,L. (2003). 
Identification of the haematopoietic stem cell niche and control of the niche size. 
Nature 425, 836-841. 
Zsebo,K.M., Williams,D.A., Geissler,E.N., Broudy,V.C., Martin,F.H., Atkins,H.L., 
Hsu,R.Y., Birkett,N.C., Okino,K.H., Murdock,D.C., and . (1990). Stem cell factor 
is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase 
receptor. Cell 63, 213-224. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102
 
RINGRAZIAMENTI 
 
Alla fine di un percorso così lungo, le persone che mi sento di ringraziare sono 
veramente tante. Innanzi tutto Cristina, per tutto quello che ho imparato dall’inizio 
ad oggi; Francesca perché è stata per tanti anni la mia paziente metà; Elena per 
avermi indirizzato e sostenuto anche se siamo così lontani (e da quanto!), e con lei 
Alessandra; Daniele, il sostegno ahimé insostituibile; Valentina ed Elisa (quanta 
pazienza che avete avuto!!!). E poi, rigorosamente in ordine alfabetico, Alessandra 
Guidi, Andrea, Diana, Ejvis, Emilia, Francesca N., Francesco, Giorgio, Leopoldo, 
Lorenzo, Lucia, Marilena, Marta, Riccardo, Sabrina, Sandra, Simona, Vera, 
Vincenzo e tutti quelli che mi sono stati vicini al CNR. 
Un particolare ringraziamento va a Sergio Ottolenghi e tutti i collaboratori 
dell’Università di Milano-Bicocca, Silvia, Antonella, Letizia, Stefania, Giuseppe, 
Claudio, Cristina, Rebecca, Roberta per il supporto teorico, materiale, logistico e 
tecnico indispensabile per questo lavoro, e quelli dell’Università La Sapienza Elisa 
Messina, Lucio, Isotta, Roberto e Giacomo. Ed anche se non hanno partecipato 
direttamente a questo lavoro, non posso dimenticare i nostri collaboratori dell’ITB 
di Milano Paolo Vezzoni, Annalisa Frattini, Antonio Musio, Maria Grazia Sacco, 
Anna Villa, ed infine tutti i docenti e gli allievi del mio Corso di Dottorato. 
Il grazie più grande a Valentina ed Anna che sono il vero motore della mia vita, per 
tutto quello che stiamo costruendo insieme nella nostra galassia lontana lontana... 
 
